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ABSTRACT
The hereditary spastic paraplegias (HSPs) represent a clinically and genetically heterogeneous 
group of neurological disorders. The phenotype is classified as pure or uncomplicated when 
the spastic paraparesis occurs in isolation and complicated when there are significant 
additional neurological or other clinical features. Inheritance may be autosomal dominant, 
autosomal recessive or X-linked.
Twenty families from the UK were identified with autosomal recessive HSP. Clinical analysis 
of affected individuals demonstrated a variety of different phenotypes with a slight 
preponderance of complicated cases. Genetic linkage analysis in the largest of these families 
identified linkage to the previously described SPG5 A locus with a maximum LOD score of 
4.84. Marker saturation analysis subsequently refined the locus to a 23.6cM region on 
chromosome 8q. In 6 of the remaining families linkage to the SPG7 locus could not be 
excluded. An affected individual from each of these families and 29 sporadic HSP cases were 
subsequently screened for SPG7 gene mutations using a combination of SSCP and 
sequencing. Three sporadic patients were found to have compound heterozygous SPG7 
mutations, five of which were novel and one that had been described previously. Muscle 
biopsies in two of the patients with SPG7 mutations failed to demonstrate histological 
evidence of oxidative phophorylation defects but did reveal mitochondrial respiratory chain 
complex I-III defects in muscle and complex I deficiency in cultured myoblasts.
A similar combination of SSCP and sequencing was used to screen a group of 12 families 
with early onset autosomal dominant HSP for SPG3A gene mutations. Only the previously 
reported R239C mutation was identified in one family suggesting that SPG3A mutations are 
relatively uncommon in this population.
Genome wide linkage analysis in a consanguineous Bedouin family from Kuwait with a 
complicated HSP phenotype including cognitive impairment, dysarthria and distal 
amyotrophy identified linkage to a 22.8cM interval on chromosome 12 with a maximum LOD 
score of 5.1. No coding sequence mutations were identied in the KIF5A gene, associated with 
pure autosomal dominant HSP, located within this region. This interval has therefore been 
proposed as a novel locus for complicated autosomal recessive HSP (SPG26).
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Chapter 1
GENERAL INTRODUCTION
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1.1 Definition
The term hereditary spastic paraplegia (HSP) is used to define a clinically and genetically 
heterogeneous group of inherited neurological disorders in which the predominant clinical 
feature is progressive spasticity and weakness of the lower limbs. The phenotype is further 
classified as “pure” or “uncomplicated” when symptoms and signs are confined to those of a 
progressive spastic paraparesis (with possible posterior column or bladder involvement) and 
“complicated” when major additional neurological or other clinical features are present 
(Harding, 1981). Inheritance may occur in an autosomal dominant, autosomal recessive or X- 
linked pattern for both pure and complicated forms of HSP.
1.2 Historical aspects
The first recorded description of HSP was published by Seeligmuller in 1876 in which he 
described four children from the same family affected by progressive spasticity and weakness 
of the lower limbs (Seeligmuller, 1876). Although often attributed with the earliest report of 
HSP, reflected in the fact that for many years the clinical syndrome came to bear his name, it 
was actually four years later that Von Striimpell (figure 1.1) reported the occurrence of a 
progressive spastic parapresis affecting two brothers (Striimpell, 1880). In his article Von 
Striimpell also referred to the father as being “a little lame”, the first suggestion of autosomal 
dominant inheritance of HSP and demonstrating what would subsequently be recognised as a 
relatively common phenomenon of variable disease expression even within the same family. 
Subsequently Von Striimpell and the French physician Lorrain would add further cases to the 
literature in the late 19th century (Striimpell, 1893; Lorrain, 1898).
In the early part of the 20th century the condition became widely recognised with numerous 
cases described throughout the medical literature across different communities. Reports began 
to appear of families in which additional neurological or other clinical features were inherited 
in association with the spastic paraparesis, although there was much debate as to whether 
these represented separate disease entities. It was not until the pioneering works of Harding in 
the 1980’s that formal criterion for the classification of HSP cases was proposed. She 
suggested the division into pure (uncomplicated) HSP in which the features were confined to 
those of a spastic paraparesis and complicated HSP where additional neurological or other
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clinical features were present (Harding, 1981). She also recognised different patterns in 
disease phenotype and progression according to the age of onset and proposed a further 
division into type I (onset before 35 years) and type II (onset after 35 years) disease (Harding, 
1984). It is only in recent years that this system of classification has been superseded through 
a greater understanding of the genetic mechanisms underlying HSP where it has become 
apparent that both pure and complicated HSP with either early or late onset may occur due to 
abnormalities in the same gene (Fink 2003).
A d o l f  v . S t r u m  p e l l
Figure 1.1 Ernst Adolph Gustav Gottfried von Striimpell (1853-1925) [from 
http://clendening.kumc.edu/dc/pc/strumpell.jpg]
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1.3 Epidemiology
HSP has been reported worldwide although the prevalence may vary between different 
communities. A number of epidemiological surveys carried out over the years have recorded 
population prevalence ranging from 0.1 to 9.6 per 100,000 (Silva et al., 1997). These are 
summarised in table 1.1. Some of these variations may be explained by differences in 
methodology between studies. Increased disease prevalence has been reported in surveys 
where secondary cases were identified by examination of all at risk relatives. The high 
proportion of asymptomatic individuals and those not seeking medical attention mean that in 
reports based solely on examination of hospital records the condition is likely to be under 
diagnosed.
Overall autosomal dominant inheritance is observed in approximately 80% of HSP cases with 
the majority of families demonstrating a pure phenotype (Reid, 1999). In the Republic of 
Ireland the prevalence of pure autosomal dominant HSP has recently been estimated to be 
1.27/100,000 (McMonagle et al., 2002). Autosomal recessive HSP is observed less frequently 
outside areas where consanguineous marriages are commonplace (Sridharan et al., 1985), 
although may account for a significant proportion of apparently sporadic cases. Complicated 
phenotypes predominate in autosomal recessive HSP families with a number of distinct 
clinical syndromes observed in isolated communities such as the Old Order Amish in the 
USA (Cross and McKusick, 1967a; Cross and McKusick, 1967b).
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Table 1.1 Epidemiological studies of HSP
Author 
(Survey year)
Country
(Region)
Population Total 
number of 
patients
Prevalence/100,000
Skre
(1968)
Norway
(Western)
725,000 31 4.3
Werdelin
(1961-1975)
Denmark
(Zealand)
1,179,000 22 1.9
Lucci
(1980)
Italy
(Reggio-
Emilia)
412,324 4 1.0
Brignolio
(1982)
Italy
(Turin)
2,327,996 31 1.3
Sridharan
(1984)
Libya
(Benghazi)
519,000 11 2.1
Polo
(1986)
Spain
(Cantabria)
510,000 49 9.6
Hirayama
(1987)
Japan 123,000,000 109 0.1
Filla
(1989)
Italy
(Molise)
335,211 9 2.7
Leone
(1991)
Italy 
(Valle 
d’Aosta)
115,270 5 4.3
Silva
(1994)
Portugal 
(Viana do 
Castelo)
250,061 5 2.0
McMonagle*
(2002)
Republic of 
Ireland
5,436,000 69 1.27
* Pure autosomal dominant HSP only
19
1.4 N europathology
Autopsy findings in patients with HSP are rarely reported. Early studies were typically of 
patients with longstanding uncomplicated HSP phenotypes and focussed on changes within 
the spinal cord. The common pathological features, shown in figure 1.2, are axonal 
degeneration of the longest motor and sensory fibres of the central nervous system i.e. the 
corticospinal tracts, the fasciculus gracilis and the spinocerebellar tracts (Behan and Maia, 
1974). Degeneration is maximal in the terminal portion of these axons (Deluca et al., 2004). 
In addition, there may be mild loss of anterior horn cells. Recently, additional cortical 
pathology including neuronal loss with tau-immunoreactive neurofibrillary tangles and 
balloon cells has been described in a patient carrying a SPG4 mutation with associated 
dementia although the significance of these changes remains uncertain (White et al., 2000).
Figure 1.2 Transverse section through the cervical spinal cord, stained for myelin with Luxol 
fast blue, in a patient with pure HSP demonstrating loss of myelinated axons in the 
corticospinal tracts and gracile fasciculi (from Harding AE. The hereditary ataxias and related 
disorders; Churchill Livingstone 1984)
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1.5 Clinical features
The predominant clinical characteristic in HSP is of a progressive spastic paraparesis. 
However, disease variability both between and within families is a striking feature. The 
disease may present at any time from early childhood, with delayed motor milestones, to late 
in adult life. The onset of spasticity is often insidious, demonstrating variable rates of disease 
progression, but without distinct exacerbations or remissions. The spectrum of resulting 
disability ranges from entirely asymptomatic (10-20% of cases) to wheelchairbound, or in the 
most extreme cases bedridden individuals (Reid, 1999). Although disease severity increases 
with time, considerable variation is present.
The commonest presenting symptoms are of stiffness in the legs leading to difficulty walking 
or running with frequent stumbling or falls, premature wear on the shoes or the observation by 
others of an abnormal gait (Durr et al., 1994). Urgency and frequency of micturition are also 
frequently reported although urinary symptoms tend to present later in the course of the 
disease (Neerup Jensen et al., 1998). Urinary incontinence may eventually become a problem 
although this is often exacerbated by problems with mobility.
The findings on neurological examination in patients with uncomplicated HSP phenotypes are 
typical of a spastic paraparesis with increased tone, a pyramidal pattern of muscle weakness, 
hyperreflexia and extensor plantar responses. However, unlike in acquired neurological 
diseases, spasticity is often out of proportion to the degree of weakness and may be the most 
disabling feature (Harding 1981). Pes cavus and other foot deformities are commonly 
reported, particularly in early onset cases (Coutinho et al., 1999). Abnormalities of posterior 
column function are a frequent finding with varying degrees of diminished vibration sense 
and proprioception (Figlewicz and Bird, 1999). Minor upper limb incoordination has also 
been described in some patients although it is unclear if this is due to sensory or cerebellar 
ataxia. Mild muscle wasting may also occur in longstanding uncomplicated cases although 
this most often reflects disuse atrophy in immobile patients. Subtle cognitive defects are 
however increasingly being recognised in patients with pure HSP phenotypes (Byrne et al., 
2000; Tallaksen et al., 2003).
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1.6 Complicated HSP phenotypes
Complicated HSP phenotypes, in which lower limb spasticity and weakness are accompanied 
by further neurological or other clinical features account for a significant proportion of cases 
(McDermott et al., 2002). Unlike pure forms of HSP they are most commonly inherited in an 
autosomal recessive fashion. The majority of X-linked cases, although rare overall, also 
present with complicated phenotypes.
A system for classification of complicated HSP phenotypes was first proposed by Harding 
and has since been regularly updated (table 1.2). A number of distinct clinical syndromes 
have been described. However, this system remains far from comprehensive, as many 
families do not fall into such clear categories. A number of syndromes have also been 
included, not generally recognised as forms of HSP, in which spasticity is a minor or variable 
feature.
Variability in clinical features has long been recognised both between and even within HSP 
pedigrees. It is now well established that mutations in the same gene may result in different 
clinical phenotypes. With advances in the understanding of the genetic basis of other 
neurological disorders it has become apparent that some families previously described as 
complicated HSP phenotypes may represent atypical presentations of other diseases such as 
Friedreich’s ataxia or Alzheimer’s disease (Gates et al., 1998; Crook et al., 1998). Eventually, 
a genetic system of classification of HSP will supersede clinically based ones, although until 
further advances in the molecular genetics of rare forms of HSP are made clinical 
classifications remain a useful tool for grouping families for research purposes and genetic 
counselling.
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Table 1.2 Complicated HSP phenotypes
TYPE CLINICAL FEATURES INHERITANCE/GENE
CRASH syndrome Agenesis of the corpus 
callosum, mental retardation, 
adducted thumbs, spastic 
paraparesis and hydrocephalus
X-linked -  LI CAM
MASA syndrome Mental retardation, aphasia, 
spasticity and adducted thumbs
X-linked -  LI CAM
Silver syndrome With distal amyotrophy AD-SPG17
Kjellin syndrome With mental retardation, 
amyotrophy and macular 
dystrophy
AR-SPG15
Troyer syndrome With dysarthria, amyotrophy 
and skeletal abnormalities found 
in Old Order Amish population
AR-SPG20 (Spartin)
Mast syndrome With dementia, cerebellar signs 
and extra-pyramidal features 
found in Old Order Amish 
population
AR-SPG21
(Maspardin)
Sjogren-Larsson
syndrome
With icthyosis and mental 
retardation
AR -  Fatty aldehyde 
dehydrogenase
Charlevoix-Saguenay
syndrome
Spastic ataxia, neuropathy, 
dysarthria and myelinated nerve 
fibres on fundoscopy most 
commonly in Quebec
AR - Sacsin
With hyperekplexia Single family with GLRA1 
mutation in which 
hyperekplexia and spastic 
paraparesis cosegregate
AD -  GLRA1
With dementia Variable degrees of cognitive 
decline
AD/AR (including 
presenilin 1, spastin)
With cataracts and 
gastroesophogeal reflux
Plus distal amyotrophy AD - SPG9
With cerebellar signs Dysarthria, nystagmus, ataxia AD/AR
With neuropathy Motor and sensory neuropathies 
described
AD/AR
With optic atrophy Decreased visual acuity AD/AR
With disordered skin 
pigmentation
Hypo and hyper pigmented skin 
lesions described
AD/AR (including 
SPG24)
With thin corpus 
callosum
Associated with cognitive 
decline, most commonly in 
Japanese
AR (including SPG11)
With epilepsy Absence, myoclonic, partial or 
generalised seizures
AD/AR
With extra-pyramidal 
features
Choreoathetosis, dystonia and 
rigidity all described
AD/AR
With syndactyly Syndactyly in upper limbs AD
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1.7 Neurophysiology
Neurophysiological studies in HSP have shown variable results although some generalisations 
can be made. Most studies have found nerve conduction studies to be normal in pure forms of 
HSP, although subclinical sensory neuropathy may be detected (McLeod et al., 1977). 
Complicated HSP phenotypes can be associated with both axonal and demyelinating 
neuropathies (Cavanagh et al., 1979).
Cortical evoked potentials typically show reduced corticospinal tract conduction velocity and 
amplitude of the evoked potential in the lower limbs (Pelosi et al., 1991). In contrast, these 
may be normal or only mildly reduced in the upper limbs (Cruz Martinez and Tejada 1999). 
Similarly, somatosensory evoked potentials usually demonstrate conduction delay in dorsal 
column fibres from the lower limbs, which is less apparent when nerves in the upper limbs are 
stimulated (Bruyn et al., 1994).
Visual evoked responses and brainstem evoked potentials have been less extensively studied 
in HSP. A delayed or reduced PI 00 and various abnormalities of the brainstem auditory 
evoked responses have, however, been reported in a small number of patients (Rossini PM 
and Cracco JB, 1987). This raises the possibility of more widespread fibre loss in central 
conduction pathways.
1.8 Management
At present there are no treatments to alter the progress of the disease. Physiotherapy remains 
the most important method for managing spasticity. In some circumstances oral anti-spasticity 
drugs such as baclofen or tizanidine may be used to reduce muscle tone although risk 
increasing lower limb weakness and adversely affecting functional capacity. Their use may 
also be limited by side effects such as somnolence. In rare circumstances where oral baclofen 
is felt to be of benefit but poorly tolerated due to sedative effects intrathecal baclofen 
delivered via a pump has proved successful (Meythaler et al., 1992). Selective use of 
botulinum toxin injection may also be considered in the treatment of spasticity (Dunne et al., 
1995). Bilateral foot drop stimulators have also been used to improve gait and reduce the risk 
of falls (Lyons et al., 2002). A number of other surgical appliances and mobility aids may be
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tried to improve daily function and prevent complications. Surgical procedures such as tendon 
transfers or tenotomies may be considered when less invasive interventions have failed.
Bladder dysfunction is a common problem occurring in up to a third of all cases (Cartlidge 
and Bone 1973). The main cause is detrusor instability, which may be helped by medications 
such as oxybutynin (Neerup Jensen et al., 1998). Genetic counselling is available for patients 
who are planning a family and HSP support groups in the UK and abroad can provide advice 
and support to patients and their families. Genetic testing for mutations in the SPG4 gene has 
recently become available in the UK.
1.9 Molecular genetics
In recent years molecular genetic research has lead to significant advances in the 
understanding of the pathophysiology underlying the various forms of HSP. At the time of 
completion of this study (September 2003), 23 HSP loci had been mapped and pathogenic 
mutations identified in 11 different genes (table 3). These developments have helped establish 
a number of common, overlapping molecular mechanisms associated with abnormal 
development or degeneration of the corticospinal pathways in HSP and other 
neurodegenerative disorders (Crosby, 2003; Reid, 2003).
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Table 1.3 Genetic classification of HSP
SPG locus Chromosomal
location
Inheritance Gene
product
Phenotype
SPG1 Xq28 X-linked L1CAM Complicated
SPG2 Xq22 X-linked PLP/DM20 Pure and complicated
SPG3 14qll-q21 AD Atlastin Pure
SPG4 2p22-p21 AD Spastin Pure and complicated
SPG5 8ql l.l-q21.2 AR - Pure
SPG6 15q 11.1 AD NIPA1 Pure
SPG7 16q24.3 AR Paraplegin Pure and complicated
SPG8 8q24 AD - Pure
SPG9 10q23.3-q24.2 AD - Complicated
SPG 10 12ql3 AD KIF5A Pure
SPG 11 15q13-q15 AR - Pure and complicated
SPG 12 19ql3 AD - Pure
SPG 13 2q24-q34 AD HSP60 Pure
SPG 14 3q27-q28 AR - Complicated
SPG 15 14q22-q24 AR - Complicated
SPG 16 Xq 11.2 X-linked - Pure and Complicated
SPG 17 1Iql2-ql4 AD BSCL2 Complicated
SPG 18 Reserved - - -
SPG 19 9q33-q34 AD - Pure
SPG20 13q 12.3 AR Spartin Complicated
SPG21 15q22.3 AR Maspardin Complicated
SPG22 Reserved - - -
SPG23 Iq24-q32 AR - Complicated
SPG24 13ql4 AR - Pure
SPG25 6q23-q24.1 AR - Complicated
AD -  autosomal dominant, AR -  autosomal recessive
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1.9.1 X-linked HSP
X-linked forms of HSP demonstrate both clinical and genetic heterogeneity. Mutations in two 
genes (LICAM and PLP) have been identified in association with X-linked HSP, with at least 
two further genetic loci postulated. While an X-linked mode of inheritance cannot be 
definitively excluded in families lacking male-to-male transmission, overall they appear to be 
relatively rare. The phenotypes associated with X-linked HSP are predominantly complicated 
with a number of distinct clinical syndromes described.
1.9.1.1 SPG1 (L1CAM)
Mutations in the gene that encodes the neural cell adhesion molecule LI (LICAM) were the 
first to be described in patients with complicated X-linked forms of HSP (Jouet et al., 1994). 
LI CAM mutations may result in a broad range of clinical presentations including varying 
degrees of hydrocephalus, mental retardation, lower limb spasticity and flexion-adduction 
abnormalities of the thumbs (Jouet et al., 1995; Fransen et al., 1996). In addition to 
enlargement of the cerebral ventricles there may also be abnormal development of the corpus 
callosum and corticospinal tracts. The term CRASH syndrome (Corpus callosum hypoplasia, 
Retardation, Adducted thumbs, Spastic paraparesis and Hydrocephalus) has been adopted for 
LI CAM mutations with variations of this constellation of features (Fransen et al., 1995).
LI is a transmembrane glycoprotein that is part of the superfamily of immunoglobulin-related 
cell adhesion molecules (Schachner, 1991). It is composed of six immunoglobulin-like 
domains and five fibronectin type-III repeats in the extracellular region, a single 
transmembrane domain and a short cytoplasmic tail (Schachner 1991). LI therefore acts not 
only as an adhesion molecule but also functions as a receptor and plays a critical role in 
growth and guidance of axons in the developing nervous system (Burden-Gulley et al., 1997; 
Joosten and Gribnau, 1998). Over 90 different LI mutations have now been described. These 
studies have revealed a striking correlation between the type of mutation in the LI CAM gene 
and the severity of the disease. Mutations that produce truncations in the extracellular domain 
of the LI protein are more likely to produce severe hydrocephalus, grave mental retardation or 
early death compared with point mutations in the extracellular domain or mutations affecting 
only the cytoplasmic domain of the protein. Point mutations in the extracellular domain
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generally produce more severe neurologic problems than mutations in just the cytoplasmic 
domain which tend to result in hydrocephalus alone (Jouet et al., 1995).
1.9.1.2 SPG2 (PLP)
Linkage analysis in additional pure and complicated X-linked HSP pedigrees identified a 
further disease locus (SPG2) at Xq21-22 (Bonneau et al., 1992). Pelizaeus-Merzbacher 
disease (PMD), an infantile-onset progressive leukodystrophy characterised by neonatal 
hypotonia, nystagmus, psychomotor retardation, spasticity, dystonia and ataxia, had 
previously been mapped to this region (Boulloche and Aicardi, 1986). PMD is caused by 
mutations in or duplications of the proteolipid protein (PLP) gene, whose protein product and 
its splice variant DM20 are major protein components of myelin in the CNS (Gencic et al.,
1989). The PLP gene was therefore considered a potential candidate as the second X-linked 
HSP gene.
Subsequently, mutations in SPG2 families were identified in PLP, confirming both pure and 
complicated forms of X-linked HSP were allelic with PMD (Saugier-Veber et al., 1994). The 
mechanisms underlying genotype-phenotype correlations between these different 
presentations associated with PLP mutations remains incompletely understood. An 
association between the trafficking capability of mutant PLP and the severity of the disease 
has been postulated (Yool et al., 2000). Disruptions of PLP mediated axonal-glial interactions 
are thought to underlie axonal degeneration identified in both patients and animal models 
(Griffiths et al., 1998). An increased dose of PLP due to gene duplication or mutations 
resulting in structurally altered translated PLP are thought to engulf the secretory pathway and 
compromise oligodendrocyte function leading to the PMD phenotype (Ellis et al., 1994). 
Conversely, mutations allowing PLP and DM20 to traverse the secretory pathway and reach 
the cell surface generally result in milder phenotypes (Cailloux et al., 2000). However, there 
may be phenotypic variation even within families indicating additional genetic and possibly 
environmental factors act as disease modifiers.
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1.9.1.3 Further genetic heterogeneity in X-linked HSP
At least two further loci for X-linked HSP have been proposed. In 1997 Steinmuller and 
colleagues studied a 4-generation family with severe X-linked spastic paraplegia in which 
affected males were quadriplegic with motor aphasia, reduced vision, mild mental retardation, 
and dysfunction of the bowel and bladder (Steinmuller et al., 1997). Disease onset occurred 
during the first 3 months of life. All females of the family were normal. By linkage and 
haplotype analysis they assigned the disease locus to Xql 1.2-q23. This region contains the 
PLP gene although no mutations were identified and the existence of a third X-linked HSP 
locus was proposed.
Subsequently, Tamagaki and colleagues described a Japanese family with a pure form of 
spastic paraplegia in 2 brothers and a maternal uncle, associated with a variant X chromosome 
that showed a faintly stained gap at Xql 1.2 (Tamagaki et al., 2000). The mother of the 
brothers also had the variant X chromosome but was clinically unaffected. The gaps were Ag- 
NOR staining positive, C-banding negative, rDNA FISH analysis positive, and alpha-satellite 
FISH analysis negative. This gap, therefore, represented an insertion of the nucleolus 
organiser region (NOR) derived from the short arm of an acrocentric chromosome. The 
variant X chromosome of the mother was randomly inactivated. It was therefore proposed that 
the NOR insertion in the affected members of the family disrupted a hitherto unknown gene 
for a pure form of spastic paraplegia, situated at Xql 1.2, and caused the disorder. This region 
has been assigned the SPG 16 locus and overlaps that mapped by Steinmuller. The diseases 
observed in the two families may therefore represent allelic disorders.
Claes and colleagues have described a further pedigree with a complicated X-linked HSP 
phenotype in which four males in two generations were affected by severe mental retardation, 
slowly progressive spastic paraplegia, facial hypotonia, and maxillary hypoplasia (Claes et al., 
2000). Linkage to the known X-linked HSP loci was excluded and although the size of the 
pedigree was too small to generate statistically significant LOD scores, multipoint linkage 
analysis indicated two possible candidate regions at Xp21.1-Xq21.3 and Xq23-Xq27.
Additional evidence for a further HSP locus on the X-chromosome comes from Starling and 
colleagues who also mapped a family with a pure HSP phenotype to an approximately 4cM 
region overlapping the PLP gene in which a mutation was excluded (Starling et al., 2002).
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Spasticity may also be a feature in a number of other well-defined X-linked disorders not 
classified amongst the HSPs.
1.9.2 SPG3A (Atlastin)
SPG3A was the first autosoaml dominant HSP locus to be mapped in 1993. Hazan and 
colleagues performed linkage analysis in 3 large pure autosomal dominant HSP pedigrees and 
identified tight linkage to chromosome 14q in one family (Hazan et al., 1993). The remaining 
two families were excluded from this region confirming that autosomal dominant HSP was 
genetically heterogeneous. In 1995 Gispert and colleagues also identified linkage to 14q in 
one of three German autosomal dominant HSP pedigrees permitting the reduction of the 
disease locus to approximately 7cM (Gispert et al., 1995). Finally Rainier and colleagues 
further refined the SPG3A locus to a 2.7cM region at chromosome 14ql l-q21 in a large early 
onset pure autosomal dominant HSP family before disease-specific mutations were identified 
in the SPG3A gene (Rainier et al., 2001).
From within the refined SPG3A interval Zhao and colleagues sequenced 13 candidate genes 
in 3 SPG3A linked pedigrees (Zhao et al., 2001). All three were found to possess pathogenic 
mutations in a gene encoding a novel protein with significant homology to the dynamin 
family of GTPases, which they named atlastin. The mutations were all situated within the N- 
terminal region, resulting in the alteration of amino acids in the conserved GTPase domain. 
Sequencing of the SPG3A gene in a further 10 early onset autosomal dominant HSP kindred, 
in which linkage analysis had not been performed, identified a further two families in whom 
all affected individuals possessed the same R239C mutation found in one of the original 
linked pedigrees. Although these families were not apparently related a distant founder effect 
could not be excluded.
Dynamins, the proteins most closely associated with atlastin, are known to play a role in a 
wide variety of vesicle trafficking events (McNiven et al., 2000). In addition, this group of 
proteins has been implicated in the maintenance and distribution of mitochondria (Pitts et al., 
1999) and have been shown to associate with cytoskeletal elements such as actin and 
microtubules (Ochoa et al., 2000). The precise mechanism by which atlastin mutations result 
in HSP remains unclear. Recent studies have confirmed that the atlastin protein is localised
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predominantly in adult brain, particularly pyramidal neurons in the cerebral cortex and in the 
hippocampus (Zhu et al., 2003). In cultured cortical neurons, atlastin co-localised most 
prominently with markers of the Golgi apparatus and membrane fractionation and protease 
protection assays confirmed that atlastin is an integral membrane protein with two 
transmembrane domains (Zhu et al., 2003). This would suggest that atlastin is predominantly 
involved in Golgi membrane dynamics or vesicle trafficking and that disruption of this 
process in the adult central nervous system underlies the neurodegenerative process.
1.9.3 SPG4 (Spastin)
The SPG4 locus on chromosome 2p was first identified in 1994 (Hazan et al., 1994; Hentati et 
al., 1994b). Linkage studies in further autosomal dominant HSP families suggested that this 
was by far the commonest cause of HSP, accounting for between 40-50% of all autosomal 
dominant cases (Hazan et al., 1999). After obtaining sequence data of the entire SPG4 locus 
Hazan and colleagues identified a potential candidate gene encoding a novel AAA protein, 
subsequently named spastin (Hazan et al., 1999). Sequencing of this gene in 7 SPG4 linked 
families confirmed the presence of missense, nonsense and splice site mutations in affected 
individuals.
SPG4 mutation screening in autosomal dominant HSP patients from around the world has 
now identified over 100 different mutations, the majority being unique to each family 
(Lindsey et al., 2000; Sauter et al., 2002; Meijer et al., 2002). The phenotype is typically of a 
pure form of HSP but with variable age of onset and disease severity (Durr et al., 1996; 
Santorelli et al., 2000a). No clear correlation has been observed between genotype and 
phenotype (Yip et al., 2003). Subtle cognitive impairment has, however, increasingly been 
recognised in association with disease progression (Byrne et al., 2000; Tallaksen et al., 2003).
Spastin is expressed ubiquitously in adult and foetal tissues (Hazan et al., 1999). Both nuclear 
and cytoplasmic subcellular localisations have been postulated ( Errico et al., 2002; Charvin 
et al., 2003;). Two isoforms exist with alternative splicing of exon 4 (Svenson et al., 2001). 
The isoform lacking exon 4 predominates in adult spinal cord tissue and as no mutations have 
yet been identified in exon 4 suggesting that this is the pathologically relevant form 
(Proukakis et al., 2002).
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Recent studies have confirmed that spastin interacts with microtubules in an ATP dependent 
manner (Errico et al., 2002). The microtubule-binding region lies within the N-terminal 
region of the protein. Studies using cells expressing mutant forms of spastin have shown 
disruption to microtubule dynamics (McDermott et al., 2003). The impairment of the 
microtubule skeleton in long axons and in particular the disruption of intracellular transport 
have therefore been proposed as a potential mechanism underlying the neurodegeneration in 
this form of HSP (Reid, 2003).
1.9.4 SPG5A
In 1994 Hentati and colleagues established linkage to a 32.8cM locus (SPG5A) at the 
pericentromeric region of chromosome 8 in four of five Tunisian autosomal recessive HSP 
families (Hentati et al., 1994). The clinical picture in all affected individuals was of early 
disease onset (ranging from 1-20 years) with bladder dysfunction and mild posterior column 
sensory impairment. An additional Tunisian family with a clinically indistinguishable 
phenotype was excluded from linkage to this locus, providing the first evidence for genetic 
heterogeneity in autosomal recessive HSP. Subsequently, linkage to the SPG5A locus was 
identified in one further Algerian family from a total of 23 Algerian and Portuguese pedigrees 
(Coutinho et al., 1999). It was therefore postulated that SPG5A linked autosomal recessive 
HSP was likely to be rare and may be restricted to the North African population.
1.9.5 SPG6 (NIPA1)
Fink and colleagues mapped the third autosomal dominant HSP locus (SPG6) to the 
centromeric region of chromosome 15q in 1995 (Fink et al., 1995a). The SPG6 critical 
interval was subsequently further refined to a 6.1cM region between D15S128 and the 
centromere (Rainier et al., 2000). This part of the chromosome is commonly involved in 
deletions in patients with Prader-Willi syndrome or Angelman syndrome, conditions 
characterised by genetic imprinting (Nicholls and Knepper, 2001). Analysis of a large 
autosomal dominant HSP family linked to SPG6 did not demonstrate any evidence of 
imprinting (Fink et al., 1995b). Ranier and colleagues therefore sequenced the non-imprinted 
genes within the SPG6 critical region and identified a missense mutation in exon 1 of the 
NIPA1 gene (159 C to G). This sequence change was not identified in control samples but the
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same mutation was found in an additional unrelated autosomal dominant HSP family, 
providing further evidence of the pathogenic nature of the mutation (Rainier et al., 2003).
The precise function of the NIPA1 protein remains unclear, although predictions based on the 
amino acid sequence and hydrophobicity analysis suggest it is an integral membrane protein 
acting as either a receptor or transporter (Rainier et al., 2003). The fact that patients with 
Prader-Willi syndrome or Angelman syndrome do not develop features of a spastic 
paraparesis would seem to indicate that mutations in NIPA1 exert a pathogenic effect through 
a gain of function or dominant negative mechanism.
1.9.6 SPG7 (Paraplegin)
SPG7 was the first autosomal recessive HSP gene to be characterised. Following linkage to 
16q24.3 in a large consanguineous Italian family with a variable complicated phenotype (De 
Michele et al., 1998), Casari and colleagues discovered a 9.5kb deletion corresponding to the 
last five exons of the SPG7 gene (Casari et al., 1998). SPG7 consists of 17 exons spanning 
approximately 52 kb. The protein product, named paraplegin, is composed of 795 amino acids 
and localises to mitochondria. It was originally found to share its closest amino acid sequence 
homology with the yeast mitochondrial metalloproteases Afg3, Real and Ymel (Casari et al., 
1998; Settasatian et al., 1999). These proteins are members of the AAA protein superfamily 
(ATPase associated with diverse cellular activities) which are found widely in both 
prokaryotic and eukaryotic cells and play an important role in a variety of cellular activities 
including cell division, transcription, organelle biogenesis, vesicle transport and enzyme 
assembly (Patel and Latterich, 1998). More specifically, yeast mitochondrial ATPases are 
known to possess both proteolytic and chaperone-like activities at the inner mitochondrial 
membrane where they are involved in the assembly and degradation of proteins in the 
respiratory chain complex (Pearce, 1999).
SPG7 mutations have been identified in patients with both pure and complicated HSP 
phenotypes (Casari et al., 1998). Muscle biopsy analysis from severely affected individuals 
revealed characteristic changes of mitochondrial oxidative phosphorylation defects including 
ragged-red fibres, cytochrome oxidase negative (COX) and succinate dehydrogenase (SDH) 
positive fibres. Electron microscopy confirmed an accumulation of abnormal mitochondria
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containing paracrystalline inclusions in a “parking lot” pattern. However, in two less severely 
affected individuals only a few scattered COX negative fibres were seen.
1.9.7 SPG8
Hedera and colleagues identified tight linkage to chromosome 8q23-24 in a large autosomal 
dominant HSP kindred in 1999 (Hedera et al., 1999a). Clinical analysis showed an 
uncomplicated phenotype indistinguishable from other pure forms of HSP (Hedera et al., 
1999b). Reid and colleagues then subsequently mapped a further family to 8q24 and refined 
the SPG8 locus from 6.2 cM to a 3.4-cM region between markers D8S1804 and D8S1179 
(Reid et al., 1999). Affected individuals from this family also had an uncomplicated 
phenotype but with an older age of onset and increased disability when compared to non- 
SPG8 linked families. Linkage to SPG8 has also been established in a Brazilian autosomal 
dominant HSP kindred in whom the authors studied muscle from affected individuals for the 
beta 1 syntrophin protein, the gene for which is located within the refined SPG8 locus (Rocco 
et al., 2000). Immunohistochemical and Western Blot studies showed that the distribution, 
expression, and apparent molecular weight of the beta 1 syntrophin protein were comparable 
to those of normal control individuals. Abnormalities of the beta 1 syntrophin gene were 
therefore felt unlikely to be implicated in this form of autosomal dominant HSP.
1.9.8 SPG9
Seri and colleagues first reported a rare form of autosomal dominant HSP in an Italian family 
associated with bilateral cataracts, persistent vomiting secondary to gastroesophageal reflux 
and distal amyotrophy (Seri et al., 1999). Linkage analysis mapped the locus for this 
syndrome to chromosome 10q23.3-q24.2 (SPG9). Subsequently a further British family with 
the same phenotype was also linked to the SPG9 locus although further refinement of the 
critical interval was not possible (Lo Nigro et al., 2000). Muscle biopsy was, however, 
performed in an affected individual in which no evidence of mitochondrial dysfunction was 
found.
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1.9.9 SPG10 (KIF5A)
After exclusion of linkage to the known autosomal dominant HSP loci Reid and colleagues 
mapped a further large pure autosomal dominant HSP family to a 9.2cM region on 
chromosome 12ql3, SPG 10 (Reid et al., 1999). Additional detailed mapping in this family 
then refined the SPG 10 locus to a 6.95cM region between markers D12S270 and D12S335 
(Reid et al., 2001). Sequencing of the sodium channel gene SCN8A excluded this as a 
candidate from within this region. Reid and colleagues then sequenced a further 30 candidate 
genes from within the SPG 10 critical interval and identified a missense mutation (A767G) in 
the motor domain of the neuronal kinesin heavy chain gene KIF5A (Reid et al., 2002). The 
mutation was not identified in over 200 control subjects supporting a pathogenic role in this 
form of HSP.
The microtubule-associated proteins of the kinesin and dynein families act as molecular 
motors that transport intracellular material along microtubules, kinesins in the anterograde 
direction and dyneins in the retrograde direction (Goldstein and Yang, 2000). The missense 
mutation in KIF5A has been predicted to disrupt stimulation of the motor ATPase by 
microtubule binding (Reid et al., 2002). This has provided some of the strongest evidence to 
date implicating defective axonal transport in the pathogenesis of HSP.
1.9.10 SPG11
A complicated form of autosomal recessive HSP with thin corpus callosum (TCC) was first 
described in Japan (Iwabuchi et al., 1994). In 1999 a recessive HSP locus (SPG11) was 
mapped to chromosome 15ql3-15 in Italian and North American families with and without 
TCC (Martinez Murillo et al., 1999). Subsequently linkage analysis showed tight linkage to 
the chromosome 15ql3-l5 locus in 10 of 13 Japanese families with HSP complicated by TCC 
and mental impairment (Shibasaki et al., 2000).
Progressive cognitive impairment is a characteristic feature of HSP with TCC (Ueda et al., 
1998). Other families have been reported with cataracts, peripheral neuropathy and ataxia 
(Nakamura et al., 1995; Okuda et al., 2002). Although most families described have been too 
small for meaningful linkage analysis on an individual basis the majority are consistent with
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linkage to 15ql3-15. However, linkage to SPG11 has been excluded in several families with 
TCC, confirming the genetic heterogeneity of this form of HSP.
1.9.11 SPG12
In 2000 Reid’s group in Cambridge mapped their third autosomal dominant HSP locus to a 
16.1-cM region on chromosome 19q, SPG 12 in a large family with an uncomplicated 
phenotype (Reid et al., 2000). Ashley-Koch and colleagues then identified an additional 
autosomal dominant HSP kindred linked to SPG 12 and refined the critical region to a 5 cM 
region between markers D19S868 and D19S220 (Ashley-Koch et al., 2001). Most recently, 
Orlacchio and colleagues described a third SPG 12 linked family allowing a further refinement 
of the critical interval to a 3.3 cM region between D19S416 and D19S220 and excluded a 
homologue of the proteasome 26S subunit ATPase as a candidate from within the refined 
locus (Orlacchio et al., 2002).
1.9.12 SPG13 (Hsp60)
SPG 13 was initially mapped to chromosome 2q24-34 in a French family with a pure form of 
autosomal dominant HSP (Fontaine et al., 2000). The genes encoding the human 
mitochondrial chaperonin Hsp60 and its co-chaperonin HsplO were also localised to this 
region and therefore considered as potential candidates in this family. Sequencing of these 
genes revealed a missense mutation, G292A, in the Hsp60 gene, co-segregating with the 
disease, resulting in the substitution of a valine residue at position 72 in the Hsp60 protein 
with isoleucine, V72I (Hansen et al., 2002). The mutation was not identified in 800 control 
chromosomes supporting a pathogenic role. To further support this a complementation assay 
demonstrated that wild-type Hsp60 but not Hsp 60 with the V72I mutation, in combination 
with HsplO was able to support the growth of E. coli whose own chaperonin genes had been 
deleted.
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1.9.13 SPG14
Using homozygosity mapping in a consanguineous family with a complicated form of 
autosomal recessive HSP, Vazza and colleagues identified a 4.5cM region on chromosome 
3q27-28 (SPG14) that co-segregated with the disease (Vazza et al., 2000). The phenotype in 
the three affected individuals included a spastic paraparesis with cognitive impairment 
including memory difficulties, visual agnosia, perseveration and confabulation. MRI of the 
brain and EEG were normal in their index case but EMG studies showed evidence of a distal 
motor neuropathy. To date this is the only family linked to the SPG 14 locus.
1.9.14 SPG15
In 1959 Kjellin first described a family with autosomal recessive HSP complicated by central 
retinal degeneration with macular pigmentation, cognitive impairment and amyotrophy 
(Kjellin, 1959). In 1997 Webb and colleagues described 2 further Irish families with a 
complicated form of autosomal recessive HSP almost identical to that described by Kjellin in 
whom they also noted dysarthria with progressive cognitive decline from the second decade 
(Webb et al., 1997). Genetic linkage analysis in these families generated a combined LOD 
score of 4.2 at zero recombination for a marker on chromosome 14 (D14S77). Subsequent 
haplotype analysis then defined an interval of approximately 19cM on chromosome 14q 
(SPG15) associated with the disease (Hughes et al., 2001).
1.9.15 SPG17 (BSCL2)
Silver syndrome, first described in 1966, is a rare form of autosomal dominant HSP 
complicated by distal amyotrophy (Silver, 1966). The small muscle weakness and wasting is 
usually most prominent in the hands (figure 1.3) but may also affect the feet. However, 
families may show evidence of incomplete penetrance with a wide variability in clinical 
expression. EMG studies in patients with Silver syndrome have shown evidence of both a 
motor neuronopthy and peripheral motor neuropathy (Windpassinger et al., 2003).
Following exclusion of linkage to any of the known autosomal dominant HSP loci, Patel and 
colleagues mapped a Silver syndrome locus (SPG 17) to a 13cM region on chromosome 
1 lql2-14 in a single large English family (Patel et al., 2001a; Patel et al., 2001b). However, a
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further family with the same clinical phenotype was excluded from this locus demonstrating 
genetic heterogeneity of the syndrome. Further linkage studies by Windpassinger and 
colleagues in four Austrian families with Silver syndrome refined the candidate gene interval 
to 5.9cM between markers D11 S I765 and D11S987 before they eventually identified 
hereozygous mutations in the Berardinelli-Seip congenital lipodystrophy (BSCL2) gene in 
families with SPG 17 linked Silver syndrome (Windpassinger et al., 2003; Windpassinger et 
al., 2004). Mutations were also identified in patients with a phenotype in which distal 
amyotrophy and weakness were the only features designated as hereditary motor 
neuronopathy type V (HMNV). These mutations were restricted to the N-glycosylation motif.
Null mutations in BSCL2, which encodes the protein seipin, were previously shown to be 
associated with autosomal recessive Berardinelli-Seip congenital lipodystrophy. Seipin is a 
transmembrane protein that is localized to the endoplasmic reticulum. The precise function of 
seipin remains unknown although its homology to midasin, an AAA (ATPases associated 
with various cellular activities) domain-containing nuclear protein that is involved in RNA 
transport, might explain how mutant forms of seipin can cause such clinically distinct 
syndromes (Windpassinger et al., 2004).
Figure 1.3 Distal amyotrophy of the small hand muscles in Silver syndrome (SPG 17)
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1.9.16 SPG19
Valente and colleagues reported a large Italian family with a late onset, relatively mild form 
of autosomal dominant HSP. Linkage analysis and haplotype reconstruction established a 
further locus (SPG19) on chromosome 9q33-q34 (Valente et al., 2002). To date this is the 
only family linked to this locus.
1.9.17 SPG20 (Spartin) and SPG21 (Maspardin)
Troyer syndrome and Mast syndrome are complicated forms of autosomal recessive HSP 
originally described in the Old Order Amish population. The cardinal features of Troyer 
syndrome are of a progressive spastic paraparesis associated with pseudobulbar palsy, distal 
amyotrophy, mild developmental delay and short stature (Cross and McKusick, 1967a). While 
there have been a few reports of similar cases outside the Old Order Amish community these 
have not manifested all the characteristic features of the Troyer syndrome and have been 
labelled Troyer-like syndromes.
In 2002 Patel and colleagues mapped the Troyer syndrome locus to a 731 kb region on 
chromosome 13ql2.3, SPG20 (Patel et al., 2002). Sequencing of all coding exons and 
adjacent splice signals within this region detected a single base deletion (11 lOdelA) in exon 4 
of a gene encoding a novel protein named spartin. The precise role of spartin remains unclear 
but the identification of a conserved functional domain, also present in spastin and molecules 
involved in endosomal trafficking (MIT domain) suggest a possible role in microtubule 
dynamics and cellular trafficking (Ciccarelli et al., 2003).
The Mast syndrome is characterised by a later onset spastic paraparesis associated with 
progressive cognitive decline (Cross and McKusick, 1967b). Cerebellar and extrapyramidal 
features may also occur in advanced cases. Homozygosity mapping in 14 affected patients 
together with haplotype analysis defined the Mast syndrome locus to a 156kb interval at 
chromosome 15q22.31, SPG 21 (Simpson et al., 2003). Sequencing of the three overlapping 
transcripts from within this region identified a single base insertion (601 ins A) in 33kDa acid- 
cluster protein gene (ACP33). This ffameshift mutation results in the truncation of the protein 
product maspardin. Maspardin localises to endosomal and trans-Golgi transport vesicles and 
is predicted to play a role in protein transport and sorting.
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Since the characterisation of these two genes responsible for Troyer syndrome and Mast 
syndrome there have yet to be any confirmed cases outside the Old Order Amish population.
1.9.18 SPG23
Autosomal recessive HSP complicated by skin hypopigmentation has been described in two 
consanguineous Arab families (Lison et al., 1981; Mukamel et al., 1985). Blumen and 
colleagues performed a genome wide screen in one of these kindred in which four individuals 
were affected by spastic paraparesis, skin hypopigmentation, microcephaly and cognitive 
impairment (Blumen et al., 2003). They mapped the gene locus to a 25cM region on 
chromosome Iq24-q32 (SPG23) with a peak LOD score of 3.05.
1.9.19 SPG24
Hodgkinson and colleagues recently reported a consanguineous family from northern Saudi 
Arabia in which children were affected by either a spastic paraparesis, sensorineural deafness 
or both (Hodgkinson et al., 2002). The two conditions segregated independently. Using 
homozygosity mapping the paraparesis mapped to a 1.8Mb region of chromosome 13ql4 
(SPG24).
1.9.20 SPG25
Zortea and colleagues reported a consanguineous Italian family in which 4 of 8 siblings were 
affected with adult-onset (range 30 to 46 years) pyramidal symptoms in the lower limbs 
(Zortea et al., 2002). In all 4 affected individuals, the paraparesis was accompanied or 
preceded by spinal pain radiating to the upper or lower limbs, with MRI showing evidence of 
spinal disc herniation in the cervical or thoracic spine. Surgery resulted in a partial 
improvement in all of them, although a compressive myelopathy was not felt to be the cause 
of the spastic paraparesis. A genome wide search with subsequent multipoint analysis yielded 
a maximum LOD score of 3.28 between markers D6S1699 and D6S314 on chromosome 
6q23.3-q24.1. This is the first example of disc herniation associated with a neurological
40
syndrome linked to a human chromosomal region and has been classified as a locus for 
autosomal recessive HSP (SPG25).
1.10 Common molecular themes
The identification of some of the genes responsible for different forms of HSP has highlighted 
a number of common molecular mechanisms underlying the pathogenesis of the disease. 
Abnrormal development of the corticospinal tracts, mitochondrial dysfunction and defective 
intracellular transport have all been shown to play a role in the pathogeneisis of various forms 
of HSP (figure 1.4). These theories are discussed further in section 8.9
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Figure 1.4 Pathological mechanisms associate with HSP genes (adapted from Wilkinson PA 
and Swash M. Hereditary spastic paraplegia and primary lateral sclerosis. In: Gilman S ed. 
Neurobiology of disease. Elsevier 2007)
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1.11 Aims of the study
The aim of this project was to study the clinical, biochemical and molecular genetic features 
of patients with autosomal recessive hereditary spastic paraplegia, predominantly in the UK 
population. This included:
1) Detailed clinical assessment of patients to establish the nature and frequency of different 
phenotypes present in the UK population.
2) Linkage analysis using markers around previously identified loci to identify the relevance 
of these in UK pedigrees and refine these loci further to allow the screening of potential 
candidate genes.
3) SPG7 gene mutation screening of patients in whom linkage analysis had not excluded the 
chromosome 16 locus.
4) Genome wide linkage analysis in autosomal recessive pedigrees not linked to any of the 
known loci in an attempt to identify new loci for autosomal recessive HSP.
5) Analysis of muscle biopsies in a selected number of patients for histology and 
mitochondrial respiratory chain function to assess the role of oxidative phosphorylation 
defects in the pathogenesis of the disease.
In addition, during the course of the study the SPG3 A gene was identified, therefore patients 
with early onset pure autosomal dominant HSP were identified from an existing database for 
screening for mutations in this gene. DNA from a Kuwaiti family with a complicated form of 
autosomal recessive HSP also became available and this family was included for genome 
wide linkage analysis.
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Chapter 2
MATERIALS AND METHODS
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2.1 Overview of general principles
2.1.1 Polymorphic genetic markers
The location of a disease-causing gene within the genome can be determined using the 
techniques of linkage mapping. This methodology is used in locating the gene by detecting 
the cosegregation of the disease phenotype with a previously positioned genetic marker of 
known location. Polymorphic markers are specific DNA sequences that have more than one 
form in the population. Many types of polymorphic marker exist, but the most commonly 
used in linkage analysis are the short tandem repeat polymorphisms, also known as 
microsatellite markers. Microsatellite DNA consists of multiple copies of motifs that can 
occur in perfect tandem, as interrupted repeats, or together with another repeat type (Weber,
1990). Microsatellite markers, which occur on average every 30kb (Beckman and Weber, 
1992) have multiple alleles and may have heterozygosity frequencies of >70%, making them 
particularly useful for genetic analysis. An additional advantage of microsatellite markers is 
that they can be readily analysed using the polymerase chain reaction, or PCR (Weber and 
May, 1989).
The amount of useful information that can be obtained from a polymorphic marker depends 
on the number of alleles and their relative frequencies in the population. A statistical measure 
of the informativeness of a marker is provided by its PIC (polymorphism information 
content), with a PIC value of >0.5 indicating high informativity (Botstein et al., 1980). PIC 
values take into account all possible allele combinations and allele frequencies in the 
population. Essentially, the more polymorphic a marker is the higher its PIC value and the 
more useful information that can be gained from it.
2.1.2 Linkage analysis and genomewide screening
During meiosis, when homologous chromosomes align and pair, one or more recombination 
events take place between each pair. This means that at some point along the DNA of the two 
chromosomes, a break occurs and the fragments are exchanged. Recombination events 
provide information about how close together two loci are. If two loci are close together, there 
is a small likelihood that recombination will occur between them. In this case, the two loci 
(e.g. a polymorphic marker and disease gene) would tend to be inherited together
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(cosegregate). If, however, they are far apart, there is a much greater chance of a 
recombination event occurring and they would show less cosegregation.
The degree of linkage is measured in centiMorgans (cM), a percentage measure. Two loci, 
which show a recombination rate of 1%, are defined as being lcM apart. A recombination 
fraction (0) describes how often any two loci are inherited together. If they are very close 
together, they invariably cosegregate, and 0 approaches 0. A recombination fraction of 0=0.5 
means that the two loci are inherited together half of the time, which would be expected if the 
two loci are completely independent (i.e. on separate chromosomes).
The LOD (logarithm of odds) score method for calculating the probability of genetic linkage 
was devised by Newton E Morgan in 1955 based on sequential testing procedures. It 
calculates the logarithm (base 10) of the likelihood that two alleles are linked divided by the 
likelihood that they are not linked i.e. the observation occurred by chance. Calculations are 
performed over a range of recombination fractions (0) between 0-0.5.
LOD (Z) = log10 [L(0)/L(O.5)]
The 0 that gives the highest LOD score is an estimation of the distance in cM between the 
two markers. A LOD score of >3.0 is taken to be statistically significant as this means that the 
likelihood of linkage occurring at this distance is 1,000 times greater than occurring by 
chance. A LOD score of <-2.0 is used to exclude linkage as this as this means it is 100 times 
more likely that the two alleles are not linked. However, a LOD score of 3.0 actually 
correlates with a probability of 20:1. This is because of the prior probability that two 
autosomal loci are linked due to the fact that they must be on one of 22 pairs of chromosomes. 
The exception is for X-linked disorders where a LOD score of >2.0 is considered to be 
significant.
Genomewide linkage analysis is a screening process using a large number of microsatellite 
markers distributed relatively evenly throughout the genome to search for a chromosomal 
region cosegregating with the disease phenotype. This process involves PCR amplification of 
the microsatellite markers. One primer in each pair is fluorescently labelled so that the PCR 
products can be analysed by a fluorescently based detection method.
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Multipoint mapping involves the genotyping of each individual of the family in which the 
disease is segregating with a genomewide set of markers. The ultimate goal of this type of 
mapping strategy is to locate the disease gene with respect to this marker framework. The 
genotype data generated is imported into a computer programme (e.g. GENEHUNTER), 
which calculates LOD scores at each marker interval of the framework map and 
simultaneously analyse information from a number of polymorphic markers. The result of this 
type of analysis is typically presented as a likelihood curve plotted against map location. The 
maximum LOD score on this curve (Zmax) represents the most likely location of the disease 
gene.
Homozygosity mapping provides a rapid means of mapping autosomal recessive genes in 
consanguineous families. This strategy assumes that affected individuals within an inbred 
population will have inherited two copies of the same ancestral mutation, and therefore will 
be homozygous for the flanking genetic material. Genotype data is analysed using compatible 
computer programmes such as HOMOZ.
2.1.3 The polymerase chain reaction (PCR)
PCR is the in vitro enzymatic amplification of a defined DNA segment many times so that it 
constitutes the only detectable DNA (Saiki et al., 1988). In cells, DNA replication begins with 
a short primer sequence, which is extended by the enzyme DNA polymerase. PCR utilises 
two primers, which are synthetic DNA sequences (typically 15-30 bp long) designed from 
existing sequence data, flanking the desired target sequence. PCR involves repeated cycles of 
denaturing to produce single-stranded DNA, primer annealing, and new strand synthesis by 
extension of the annealed primer using a thermostable DNA polymerase. Taq polymerase, 
isolated from Thermus aquaticus (a thermophilic bacterium) is most commonly used 
(Strachan and Read, 1997). The initial products of the PCR act as templates for subsequent 
rounds of synthesis with initial exponential amplification of the target sequence. During the 
early cycles there is exponential amplification, then in later cycles there is linear product 
accumulation, and eventually a “plateau” is reached. Twenty to thirty cycles will amplify the 
target sequence about 105-fold from lpg of genomic DNA (Davies and Read, 1992).The 
primers are the most important determinant of PCR efficiency, and the annealing temperature
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depends almost entirely on their sequence. The concentrations of MgCh and dNTPs in the 
PCR mixture are also important for efficient and specific DNA amplification.
2.1.4 Polyacrylamide gel electrophoresis (PAGE)
Polyacrylamide gels are used to separate small DNA fragments (<500bp). A voltage is 
applied across the gel and acts on the negatively charged DNA. The principle underlying 
PAGE is that smaller DNA fragments are able to move faster through the gel matrix than 
larger DNA fragments. PAGE is very sensitive and has a resolving power of up to lbp. The 
size of the pores in the gel through which DNA migrates determines the size of the fragment 
that can be resolved. The pore size can be varied by adjusting the concentrations of 
polyacrylamide and the cross-linking reagent. Non-denaturing and denaturing polyacrylamide 
gels can be used to separate double-stranded and single-stranded DNA fragments, 
respectively. In denaturing PAGE, double-stranded DNA samples are denatured, usually by 
heating the DNA in a solution containing a chemical denaturant, for example formamide. 
These samples are then loaded onto polyacrylamide gels also containing a chemical 
denaturant, such as urea, to ensure that the DNA strands remain single-stranded, and an 
electric current is applied across the gel. In non-denaturing PAGE, the samples are 
electrophoresed in the absence of any denaturant.
2.1.5 DNA sequencing
DNA sequencing is a technique used to determine the sequence of bases in a length of DNA. 
The DNA sequence of a particular gene can indicate the function of the protein product, as 
well as the effect of a specific mutation, and can point to functional domains that may be 
present in related genes. The process is similar to PCR; however, there is one additional 
ingredient added to the thermocycling reaction. A proportion of the dNTPs are 
dideoxyribonucleotides (ddNTPs). These prevent further elongation of the DNA sequence. If 
appropriate concentrations of each of the four dNTPs and ddNTPs are included, a series of 
incompletely elongated chains is produced, each differing by one base pair. The sequence can 
then be determined by running each reaction (containing the different ddNTP) on a 
polyacrylamide gel. However, most modem strategies for DNA sequencing used today 
employ a fluorescent detection system incorporating fluorescently-labelled nucleotides. The
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fluorescently-labelled reaction products are then electrophoresed on a DNA sequencer (gel or 
capillary based systems) which uses a laser detection method.
2.1.6 Mutation screening
Determination of the intron/exon organisation of a gene of interest is the first step toward 
screening the gene for disease-associated mutations. Once the introns and exons have been 
identified, primers can be designed to amplify each exon plus a sufficient amount of flanking 
intronic sequence so that splice donor and acceptor site sequences are included. The amplified 
PCR products can then be subjected to rapid mutation screening methods, such as single 
strand conformation polymorphism (SSCP) analysis, where the sample of interest can be 
compared with the wildtype sequence, or can be sequenced directly.
2.1.7 Single strand conformation polymorphism (SSCP) analysis
Although direct sequencing is the most accurate means of detecting mutations, it can be very 
time consuming. Other techniques such as SSCP can provide a more rapid approach for 
screening large numbers of samples for mutations after which sequencing can be carried out if 
necessary. SSCP exploits the fact that the secondary structure of a particular DNA sequence 
can be altered by a mutation in that sequence (Orita et al., 1989). This can change the rate of 
mobility of a single-stranded DNA sequence in a non-denaturing acrylamide gel. Under the 
correct conditions, such as the appropriate percentage of acrylamide gel and ideal temperature 
(usually 4°C or 10°C) band shifts are detectable, allowing the differentiation between the 
normal sequence and an altered sequence. Mutation detection with SSCP analysis is detects 
approximately 90% of mutations (Fan E et al., 1993). However, this method is limited by the 
requirement for DNA fragments of usually less than 400bp.
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2.1.8 Mitochondrial respiratory chain function
Located on the inner mitochondrial membrane, the respiratory chain is composed of more 
than 80 peptides organised into 5 enzymatic complexes (I-V). The overall function of the 
mitochondrial respiratory chain is to produce ATP from the reduction of oxygen to generate 
energy for cellular function. Electrons generated by donors in intermediary metabolism are 
received and sequentially transferred through redox groups to final acceptor, oxygen. Free 
energy generated is then used to pump protons from mitochondrial matrix to intermembrane 
space. This generates an electrochemical gradient across inner mitochondrial membrane. 
Proton flux back into mitochondrial matrix through Complex V is then coupled to ATP 
synthesis.
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Figure 2.1 Overview of the mitochondrial respiratory chain (modified from metabolic 
pathways of biochemistry at http://www.gwu.edu/~mpb/oxidativephos.htm)
Diseases associated with defects in respiratory chain function may arise from mutations in 
mitochondrial DNA or nuclear genes encoding proteins essential for mitochondrial function. 
The function of individual components of the respiratory chain can be assessed by uncoupling 
the chain using specific inhibitors to individual complexes. A large number of 
neurodegenerative and other disorders have now been associated with specific defects in 
mitochondrial respiratory function (Orth and Schapira, 2001).
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2.1.9 Enzyme assays and spectrophotometry
A spectrophotometer measures either the amount of light absorbed or transmitted. All of the 
mitochondrial enzyme assays utilise differences in absorbance. Light of a given wavelength 
(lambda = X) is split and passes along two different paths. The light passes through the "test" 
cuvette along one route and the "reference" cuvette along the other. The light is then 
converged and passes through a photomultiplier tube (PM). The difference in absorbance is 
then measured. The spectrophotometer measures the difference in absorbance between the 
front and the back cuvettes. Initiation of the majority of mitochondrial enzyme reactions 
results in the generation of a relative increase in absorbance, compared to the reference, due to 
the production of increasing amounts of chromophore. This generates an easily interpretable 
incline on the resulting graph. If the reaction results in a reduction in the amount of 
chromophore and hence absorbance the positions of the test and reference cuvettes are 
reversed so that an incline is still produced on the graph, making calculations (i.e. reaction 
rates) easier to perform.
2.1.10 Muscle biopsies and tissue preparation
As defects in mitochondrial oxidative phosphorylation had been implicated in the 
pathogenesis of some forms of HSP, affected individuals who had agreed to participate in the 
research were asked if they would be willing to undergo a muscle biopsy for histological 
assessment and respiratory chain function assays. Age and sex matched control tissue was 
obtained from biopsies previously performed on patients who had no abnormal physical signs 
and normal histological appearance.
Samples of muscle tissue were obtained using open muscle biopsy from the vastus lateralis 
muscle under local anaesthetic. The majority of the sample was instantly frozen in liquid 
nitrogen and sent for histological assessment including Trichrome Gomori, Cytochrome 
oxidase (COX) and succinate dehydrogenase (SDH) staining. Remaining muscle from this 
sample was then available for respiratory chain function assays and electron microscopy. A 
small piece of muscle tissue was also placed directly into tissue culture medium for myoblast 
culture.
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2.2 General solutions
Lysis buffer
0.32M Sucrose (BDH) 
lOmM Tris, pH7.5 (Sigma)
5mM MgCl2 (BDH)
1% Triton X-100 (Sigma)
TE buffer
lOmM Tris (Sigma), pH7.5
ImM EDTA (ethylenediaminetetraacetic acid; BDH), pH8.0
10X PCRIV buffer (ABgene)
750mM Tris-HCl (pH8.8 at 25°C)
200mM (NH4)2S04 
0.1% Tween-20
This buffer is supplied containing 15mM MgCl2 or with 25mM MgCl2 separately
10X Agarose gel loading buffer
20% Ficoll 40 (Sigma)
0.02% Bromophenol blue (BDH)
0.02% Xylene cyanol (Sigma)
Distilled water
DNA molecular weight marker X, 0.07-12.2kb
20pl DNA molecular weight (lpg pi'1) [Invitrogen]
40pl 10X Agarose gel loading buffer 
40pl 0.1M NaCl 
140pl TE buffer
20X TAE (Tris Acetate Electrophoresis) buffer (ND)
2.0M Tris-acetate
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50mM EDTA
10X TBE (Tris Borate Electrophoresis) buffer (ND) 
0.89M Tris-borate, pH8.3 
20mM EDTA
10X Denaturing loading buffer
98% Formamide (Sigma)
0.05% Bromophenol blue (BDH)
0.05% Xylene cyanol (Sigma)
Blue dextran loading buffer
50mg/ml blue dextran containing 25mM EDTA (AB) 
Diluted 1 in 10 with formamide (Sigma)
20X SSC
3M NaCl
0.3M Sodium citrate (pH7.0)
Denaturing solution
1.5MNaCl (BDH)
0.5M NaOH (BDH) Adjusted to pH12.0
Neutralising solution
1.5M NaCl (BDH)
0.5M Tris (Sigma) Adjusted to pH6.0
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2.3 General protocols
2.3.1 DNA extraction from 5ml of whole blood
DNA extractions were performed using a standard phenol-chloroform procedure (Kunkel et 
al., 1977). This begins with cell lysis using lysis buffer with centrifugation at 8000rpm for 10 
minutes at 4°C in a Beckman J2-HS or a Sorvall RC5B centrifuge in a 30ml round-bottom 
centrifuge tube (Sarstedt) to pellet the cell nuclei. The pellets are then resuspended in 5ml of 
0.075M NaCl/0.024M EDTA (pH 8.0), and 250pl SDS [sodium dodecyl sulphate; 10%; 
(ND)] and lOOpl proteinase K (lOmg/ml) added to lyse nuclear membranes and to digest 
proteins, respectively, and incubated overnight at 37°C. Ensuring that no lumps of pellet are 
visible, then an equal volume of pre-equilibrated phenol saturated with 0.1M Tris, pH7-8 
(Rathbum) is added, followed by centrifugation at 8000rpm for 10 minutes at room 
temperature. The upper aqueous layer was then transferred into a fresh tube and an equal 
volume of 24:1 chlorofomuisoamyalcohol (BDH) added to remove traces of phenol, and 
centrifuged at 8000rpm for 10 minutes at room temperature. Again, the upper aqueous layer is 
transferred to a fresh tube, and 10ml of absolute ethanol (BDH) added to precipitate the DNA, 
which is then spooled onto a sterile loop and dissolved in an appropriate volume of TE buffer 
(pH7.5) depending on the size of the spooled DNA.
2.3.2 PCR for primers not fluorescently-labelled
A master mix was made up such that each aliquot contained the following (Table 2.1), 
if 1.5mM Mg required for PCR reaction:
Table 2.1 PCR reaction mixture
PCR reaction component Volume (pi)
Forward primer (50pmol pi'1) [Sigma-Genosys] 1.0
Reverse primer (50pmol pi'1) [Sigma-Genosys] 1.0
5mM dNTPs (Abgene) 1.0
Reaction buffer IV (10X) with 15mM MgCh (ABgene) 2.5
Red Hot Taq DNA polymerase (0.2 units pf ; ABgene) 2.0
Distilled water 15.5
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Then 200ng of DNA (in a 2pi volume) was added to the appropriate 0.5ml PCR tube 
(Sarstedt) to give a final volume of 25pl. Amplifications were performed using a touchdown 
method (Roux, 1995) in a GeneAmp PCR system 9700 (AB), a Techne Genius PCR machine, 
or Hybaid MBS 0.5G PCR machine (Table 2.2).
Table 2.2 PCR cycle programme
Number of cycles Temperature
(°C)
Time
(seconds)
96 30
2 Primer-specific temperature + 4 30
72 30
96 30
2 Primer-specific temperature + 2 30
72 30
96 30
35 Primer-specific temperature 30
72 30
The PCR conditions for amplifying the microsatellite markers analysed by polyacrylamide gel 
electrophoresis were individually optimised.
2.3.3 Agarose gel electrophoresis
PCR products mixed with 2pl of agarose gel loading buffer were visualised after 
electrophoresis alongside a DNA molecular weight marker, in IX TAE in 2%  agarose (BM, 
GB) gels containing ethidium bromide (Sigma) at 0.5pg ml'1.
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2.3.4 Polyacrylamide gel electrophoresis (PAGE)
Amplified microsatellite markers were subsequently size fractionated by denaturing PAGE 
with denaturing loading buffer in 8% or 10% denaturing polyacrylamide (Amresco or ND) 
gels (Tables 2.3A and 2.3B), in IX TBE preheated to approximately 60°C. The amount of 
PCR product mixed with 2pi of denaturing loading buffer and loaded on the polyacrylamide 
gels was varied dependent on the strength of the product visible on agarose gel 
electrophoresis. PAGE was carried out at 50mA for an appropriate length of time such that 
the different sized alleles that had been amplified could be differentiated on the 
polyacrylamide gel. The gels were subsequently silver stained and fixed.
Table 2.3 Protocol for making an 8% denaturing acrylamide gel (25ml) using a pre-prepared 
solution
Gel component Volume/gel
* GenePAGE 8% solution (Amresco) 25.0ml
TEMED (N, N, N’, N’-tetramethylethylenediamine; Sigma) 40pl
25% APS (ammonium persulphate, Sigma) 40pl
* GenePAGE 8% solution contains 7.6% (w/v) acrylamide, 0.^ % (w/v) bisacry
urea, 0.089M tris, 0.089M boric acid, 2mM EDTA.
2.3.5 Silver staining
Polyacrylamide gels were placed in a fixing solution of 10% ethanol (BDH) and 0.5% glacial 
acetic acid (BDH) for at least 15 minutes, left in 0.1% silver nitrate (Sigma or BDH) for 5-10 
minutes, stained in 1.5% NaOH (BDH), 0.15% formaldehyde (BDH), then in 0.75% sodium 
carbonate (BDH) for 15 minutes. The gels were thoroughly rinsed in distilled water between 
each stage. The visualised size-fractionated alleles were given a number and then individuals 
were assigned a genotype.
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2.3.6 Genome wide marker analysis
A genome wide screen was performed using the ABI PRISM Linkage Mapping Set Version 2 
(Applied Biosystems) which contains fluorescently labelled primer pairs for the amplification 
of 384 microsatellite markers, with an average spacing of lOcM. Each marker was amplified 
individually, however, the markers are arranged into 26 panels each containing non­
overlapping sized markers labelled with three different flourophores. Each panel of markers 
was therefore pooled together, allowing simultaneous electrophoresis and laser detection.
2.3.7 PCR with fluorescently labelled primers
A PCR master mix was made up for each of the primer pairs (table 2.4). 9.2pl of this mix was 
loaded into 96 well plates (AB gene) and 0.8pl of DNA at 50ng/pl added to each reaction 
mixture. PCR amplifications were performed in the Hybaid MBS 0.5G PCR machine using 
the recommended cycle programmes (table 2.5).
Table 2.4 PCR mixture for amplification of fluorescently labelled markers
PCR master mix component Volume (pi)
Primer mix* (Applied Biosystems) 1.0
True Allele PCR premix** (Applied Biosystems) 6.0
Distilled water 2.2
* Contains forward (labelled) and reverse primers combined at lOpM concentration in a 
solution of lOmM Tris, ImM EDTA at pH 8.0
** Contains an optimised mixture of AmpliTaq Gold DNA polymerase, buffer, MgC^ and 
dNTPs
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Table 2.5 Recommended cycle programme for amplification of fluorescently labelled 
microsatellite markers
Number of cycles Temperature (°C) Time (seconds)
1 95 720
94 15
10 55 15
72 30
89 15
25 55 15
72 30
1 72 600
2.3.8 Genotyping of labelled products
PCR products were checked for successful amplification by electrophoresis in 2% agarose 
gels. Panels of PCR products were then pooled together and added to a solution containing 
HiDi formamide and the Gene-scan 500 marker in 96 well plates (table 2.6). This loading 
mixture was the denatured at 96°C for 3 minutes and immediately cooled on ice, prior to 
running on the ABI 3100 automated sequencer. The ABI 3100 was set up with a 36cm 
capillary array loaded with POP4 linear flowable polymer. Samples were added to the 
capillaries with a 22 second lKvolt injection and underwent electrophoresis at 60°C, lOOpA 
for 25 minutes.
Table 2.6 Loading mixture for detection on the ABI3100 automated sequencer
Loading mixture component Volume (pi)
Pooled PCR products 2.0
4nM Genescan-500* (Applied Biosystems) 0.5
HiDi Formamide (Applied Biosystems) 9.5
* Genescan-500 ROX fragment sizes: 35, 50, 75,100,139,150, 160,200, 250, 300, 340, 350, 
400, 450, 490, 500
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2.3.9 Data analysis
Alleles were sized using GeneScanTM Analysis software (Applied Biosystems), with 
reference to the internal lane size standard, to within 0.01 bp accuracy. The data files 
generated were imported into the Genotyper 3.7 software (Applied Biosystems) and the 
markers then ordered and genotyped. The resulting microsatellite marker information was 
then assessed for homozygosity and where appropriate imported into the Genehunter (version 
2.1) software which calculates haplotype information and multipoint LOD scores. Two-point 
LOD scores were also calculated using the subprogram MLINK (version 5.1) of the 
LINKAGE program package. All programs used for linkage analysis were accessed through 
the Human Genome Mapping Project (HGMP) website.
2.3.10 PCR product purification
DNA of interest was amplified by PCR in a total volume of 50pi. Of this 5pi was 
electrophoresed on a 2% agarose gel as described in section 2.4.4. The remaining 45pl of 
PCR product was then purified using a spin column protocol [QIAquick PCR Purification Kit 
(QIAGEN) or GENECLEAN Turbo for PCR Kit (QBiogene)] to remove primers, 
unincorporated nucleotides, and polymerases, and eluted into 20pl with distilled water.
2.3.11 DNA sequencing protocol
3 pi of spin purified PCR product was used as a template in each sequencing reaction using the 
ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit (AB) [Table 2.7]. The 
sequencing reaction amplifications were performed using the cycle programme in Table 2.8. 
Both strands of each PCR product were sequenced.
Table 2.7 Sequencing reaction protocol
Sequencing reaction component Volume (pi)
BigDye Terminator (AB) 2.0
Primer (Spmolpf1) 1.0
Distilled water 4.0
Purified PCR product 3.0
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Table 2.8 DNA sequencing cycle programme
Number Temperature Time
of cycles (°C)
96 30 seconds
25 50 15 seconds
60 4 minutes
The sequencing reaction product was then purified using the DyeEx Spin Kit (QIAGEN) 
according to the recommended protocol to remove unincorporated BigDye™ terminators. The 
final eluent was then dried on a PCR machine at 60°C. Finally 10pl of Hi-Di formamide (AB) 
was added to the dried sequencing product before being denatured, cooled, and run on an 
ABI3100 automated sequencer (capillary injection-based) [AB].
2.3.12 Single strand conformation polymorphism (SSCP) analysis
PCR products were mixed with denaturing loading buffer and electrophoresed in 0.6X TBE 
usually using 0.55X or 0.6X MD gels (Table 2.9) for an appropriate length of time at 10°C 
(constant 250V) using BioRad Protean II equipment. DNA was visualised by silver staining.
Table 2.9 Protocol for preparing a 0.55X or 0.6X MD acrylamide gel for SSCP analysis
Component of gel mixture Volume
0.55X 0.6X
2X SequaGel MD (ND) 9.625ml 10.500ml
1 OX TBE 2.100ml 2.100ml
Distilled water 23.275ml 22.400ml
TEMED (Sigma) 70pl 70pl
25% APS (Sigma) 70pl 70pl
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2.3.13 NADH-COQ1 reductase assay (mitochondrial complex I activity)
The NADH-COQ1 assay measures the rate of oxidisation of NADH to NAD+ by complex 1 
of the mitochondrial respiratory chain. Ubiquinone accepts the electrons and is reduced to 
Ubiquinol. Cyanide inhibits complex IV (cytochrome c oxidase) activity and the Rotenone is 
added because it specifically inhibits mitochondrial NADH COQ1 reductase to terminate the 
reaction.
The homogenised muscle or mitochondrial preparation from cultured myoblasts may be used 
undiluted or diluted (e.g. 1:20) in homogenisation buffer, according to its specific nature. 
Freeze-thawing the sample a total of 3 times in liquid nitrogen disrupts the mitochondrial 
membranes, exposing the enzymes in an intact and metabolically active state.
The ubiquinone is supplied at an unknown concentration. To determine the amount of 
ubiquinone required for the reaction sodium borohydride is used to reduce the ubiquinone to 
its non-absorbing state. The absorbance change is calculated using the spectrophotometer and 
the amount of ubiquinone required for each reaction is calculated using the formula
0.3/absorbance change x 20.4pl. The remaining reagents and volumes required for the 
NADH-COQ1 assay are shown in table 2.10
Table 2.10 NADH-COQ1 assay reaction mixtures
Reagent Reference cuvette Test cuvette
25mM K+ Phosphate 
Buffer + lOmM MgCl2, 
(pH 7.2)
800pl 800pl
5mM NADH (3.6mg/ml) 30pl 30pl
lOOmM KCN (6.5mg/ml) lOpl lOpl
50mg/ml BSA 50pl 50pl
dd H20 lOOpl 100 - (x + y)pl
Homogenised muscle or 
mitochondrial preparation
xpl
5mM Ubiquinone - yul
X = 5 ,10orl5 ,Y  = amount previously calculated
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The NADH-C0Q1 assay is performed as follows:
1. Select the “NADH Q1 Red” programme on the Hitachi spectrophotometer (Wavelength = 
340nm, Temp = 30°C).
2. Set the data scale form -0.05 to 0.25.
3. Set up 6 cuvettes (3 reference & 3 test) loaded with 800pl of buffer, 30pl of NADH, lOpl 
of KCN & 50pl of BSA. Add lOOpl of ddH20 to the 3 reference cuvettes. Mix (parafilm) 
and place in the water bath to pre-warm.
4. Add lOOpl of pre-warmed ddH20 - (xpl (homogenised muscle) + ypl (as previously 
calculated ubiquinone) and xpl of homogenised muscle to one test cuvette, mix thoroughly 
(parafilm) and load into the back of the spectrophotometer.
5. Load one reference cuvette into the front of the spectrophotometer.
Autozero, start the assay and leave to flatline (for approx lA  minute).
6. Add ypl of ubiquinone to the back test cuvette. The rate is visualised as an increase in 
absorbance. Leave to run for 3-4 mins or until the absorbance reads 0.2.
7. Add lOpl of Rotenone to both cuvettes (test cuvette first), take out, mix (parafilm) and 
replace. The rate of reaction should decrease at this point due to inhibition of the Rotenone- 
sensitive component of the enzyme activity.
8. Leave to run for a further 3-5 minutes to give a linear rate.
9. Stop and scan the trace adding 4 cursor points as shown in the figure below, taking care to 
avoid the non-linear region of the incline.
10. Calculate the reaction rates between the first and second pair of points and subtract the 
latter from the former to give the rotenone sensitive rate which is equivalent to complex I 
activity (figure 2.2).
Rotenone added
ABSORBANCE t
Undesirabl
Linear
UQ1 added
TIME ->
Figure 2.2 Example of graph for calculation of complex I activity
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The M extinction coefficient of NADH is 6.22 x 103. However, because the contribution of 
ubiquinone reduction to the absorption at 340nm this means that the true value in the assay is 
6.81. The reaction rate is calculated as follows:
Absorbance change 1000 1
Rate (nmol/min/mol) = Time X X
pi sample 1000
6.81 x 103
2.3.14 Succinate cytochrome C assay (mitochondrial complexes II and III activity)
The succinate cytochrome C assay measures the rate of reduction of cytochrome C. It is 
performed at 30°C using a wavelength of 550nm. Cyanide inhibits complex IV activity. 
Antimycin A is used to terminate the reaction, as this is a potent inhibitor of mitochondrial 
succinate cytochrome C activity. Muscle tissue or mitochondria are prepared as for the 
NADH-COQ1 assay and freeze thawing is again required to expose the enzymes in a 
functionally active state. The mitochondrial enzyme is activated prior to its addition to the test 
cuvette, during which time the fumarate in complex II is replaced by succinate. If the reaction 
is not initiated prior to its addition, a non-linear graph will be produced as the rate of reaction 
increases until it reaches its maximum. This makes the desired calculations more difficult. 
The reagents and volumes required for the succinate cytochrome C assay are shown in table
2 . 11.
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Table 2.11 Succinate cytochrome C assay reaction mixtures
Reagent Reference cuvette Test cuvette
166mM K+ Phosphate 
Buffer pH 7.4
600pl 600pl
15mM (K2) EDTA 
(6.1 mg/ml)
20pl 20pl
2mM Cytochrome C 
(25mg/ml)
50pl 50pl
lOOmM KCN (6.5mg/ml) lOpl lOpl
50mg/ml BSA 50pl 50pl
dd H20 320pl 320 - (x + y)pl
Homogenised muscle or 
mitochondrial preparation
xpl
500mM NA+ Succinate 
(675mg/5ml)
yul
2mM Antimycin A 
(1 mg/ml)
10|xl
X = 5,10 or 15, Y = 40
The succinate cytochrome C assay is performed as follows:
1. Select the “Succinate Cytochrome C” programme on the Hitachi spectrophotometer. 
Wavelength = 550nm, temperature = 30°C.
2. Set the data scale at 0-0.4.
3. Load 6 cuvettes with buffer (600pl), EDTA (20pi), cytochrome C (50pl) and ddH20 (3 ref 
cuvettes = 320pl: 3 test cuvettes = 320pl - total volume of succinate (y = 40pl) and x, where 
x = volume of homogenised muscle added e.g. lOpl.
4. Load 3 eppendorfs with identical volumes of (40pl) Na Succinate and (lOpl) KCN.
5. Add the chosen volume of homogenised muscle e.g. lOpl, to one of the eppendorfs and 
place it in the water bath for 5 minutes at 30°C to activate the enzyme.
6. After 4 minutes of the time has elapsed add lOpl of KCN to the reference cuvette. Mix and 
load both of the cuvettes, (reference - back: test - front) into the spectrophotometer.
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7. Autozero the spectrophotometer and start the assay. The trace should be flat-lining as the 
sample cuvette doesn't contain any substrate or mitochondria.
8. When the full five minutes has elapsed, add the entire contents of the pre-warmed 
eppendorf (Na succinate, KCN & mitochondria) to the test cuvette and mix.
9. Run the assay for an absorbance change of approx 0.4 then add lOpl of Antimycin A to the 
test cuvette, mix and run for a further 4-5 minutes. The trace should flat-line from this point.
10. Using the "SCAN TRACE" function, 4 cursor points are plotted as shown on the diagram 
below. The Rate of Reaction is calculated between the first two points and between the 
second two points (figure 2.3).
Absorbance
t
Antimycin A
▼s. Na succinate
Time -»
Figure 2.3 Example of graph for calculation of complex II/III activity
The M extinction coefficient of reduced cytochrome c is 19.2 x 10 , which gives the answer in 
moles. The rate of reaction is calculated as follows:
Absorbance change 1000 1
Rate (nmol/min/mol) = Time X X
pi sample 1000
19.2 x 103
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2.3.15 Cytochrome C oxidase assay (mitochondrial complex IV activity)
The cytochrome c oxidase assay measures the rate of oxidation of reduced cytochrome c. 
Cytochrome c initially comes in its oxidised form and is reduced using an excess of ascorbate. 
Any residual ascorbate is then removed by dialysis. The molar extinction coefficient for 
reduced cytochrome c is 19.2 x 10 at 550nm. Using this extinction coefficient it can be 
calculated that 50pM reduced cytochrome c, the required concentration of cytochrome c for 
the assay, produces an absorbance of 0.96. This is therefore used as a starting point for each 
reaction. As with complex I and complex II/III assays the mitochondrial enzymes in the 
sample are released by freeze thawing in liquid nitrogen. Potassium ferricyanide is used to 
completely oxidise cytochrome c in the reference sample.
The reagents and volumes required for the succinate cytochrome c assay are shown in table
2 . 12.
Table 2.12 Cytochrome C oxidase assay reaction mixtures
Reagent Reference cuvette Test cuvette
0.1M K+ Phosphate Buffer pH 7 lOOpl lOOpl
Reduced Cytochrome C (50pM) yul yul
ddH20 900 - (x + y)nl 900 - (x + y)nl
Homogenised muscle or mitochondria - xpl
0.1M K+ Ferricyanide xpl -
X = 5,10 and 15, Y = amount of reduced cytochrome c to give an absorbance of 0.96
The cytochrome c oxidase assay is performed as follows:
1. Select the “CYTOX” programme on the Hitachi spectrophotometer. Wavelength = 550nm, 
temperature = 30°C.
2. Load 6 cuvettes (3 test: 3 reference) with buffer (lOOpl) and the previously calculated 
desired volume (ypl) of reduced cytochrome c.
3. To the test cuvettes add 900pi of dd H2 O - (xpl of homogenised muscle + ypl of reduced 
cytochrome c).
4. To the reference cuvettes add 900pl of dd H2 O - (ypl of reduced cytochrome c + xpl of K+ 
ferricyanide e.g. lOpl).
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5.Pre-warm the cuvettes in the water bath at 30°C.
6. Load one reference cuvette into the back of the spectrophotometer and one test cuvette in 
the front.
7. Autozero the machine.
8. Add 10pi of K+ Ferricyanide to the back reference cuvette to oxidise the reduced 
cytochrome c and mix well. The difference in the content of reduced cytochrome c between 
the test and reference cuvettes is now maximum and the absorbance should read 0.96 ± 0.02.
9. Start the assay.
10. After 30 seconds, take a note of the absorbance (t = 0) and initiate the reaction by adding 
the mitochondrial enzyme, i.e. xpl of homogenised muscle to the front test cuvette. The 
sample needs to be added as rapidly as possible and mixed well.
11. Repeat the assay 5 times using different volumes of homogenised muscle sample.
12. The rate is visualised as a decrease in absorbance. Expand the time scale from 0-5 minutes 
(need a minimum of 3 minutes of running time) and maximise the data scale so that the graph 
fills the entire screen. The graph is then printed for further calculations (figure 2.4).
t = 0
Muscle tissue added
ABSORBANCE t
TIME - »
Figure 2.4 Example of a graph for calculation of complex IV activity
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Because the reaction is rigorously first order with respect to cytochrome c (i.e. non-linear) it 
is best to calculate the pseudo first order rate constant k. On the graph draw a tangential 
straight line as shown and extrapolate the absorbance back to the x-axis, taking care to avoid 
any artifactually steep initial region of the slope. To give time (t) = 0, take the point that is 
mid-way during the time taken to add the sample. Draw a line from this point horizontally 
across the graph and mark along it t = 1, 2 and 3 minutes from the calculated time point t = O 
using original time scale of the graph as a reference. Draw down to the trace from points t = 1, 
2, & 3 and calculate the absorbance values at these times.
P lo t: In A t=o - In (A t=o - A t=n) against time (t).
Where In = the natural log, n = time (mins) and At (absorbance at t= 0) = approx 0.96 (insert 
value for each individual assay), by entering the absorbance values at t = 0, 1, 2, & 3 and 
volume in pis of mitoprep (including any dilution in HB) used for each assay in the 
programme CYTOCALC/cytocall (DAN). Cytocall automatically draws the graph and gives 
the k value. The K value (gradient) is the Cytochrome c rate constant and is expressed as the 
change in absorbance/min/ml. In order to convert this to absorbance/min/pl the value is 
multiplies by 1000/x (where x is the volume of homogenised muscle in pi used in the assay).
2.3.16 Citrate synthase assay
Citrate synthase is a mitochondrial matrix enzyme. It catalyses the reaction between 
oxaloacetate (OAA) and acetyl CoA to generate citrate and liberate free thiol groups.
Citrate
Oxaloacetate (OAA) + Acetyl CoA ------------► Citrate + CoA-SH
Synthase
DTNB (5,5-dithio bis-2-nitrobenzoid acid) then binds free thiol groups to produce DTNB- 
CoA which is yellow and absorbs at 412nm.
Citrate
OAA + Acetyl CoA* + DTNB *  Citrate + DTNB-CoA
Synthase
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As it is not part of the mitochondrial respiratory chain its activity is used as a marker for the 
number of mitochondria in a given sample. Mitochondrial respiratory chain complex enzyme 
activities are therefore divided by citrate synthase activity to estimate activity independent of 
the number of mitochondria in each sample. The reagents and volumes required for the citrate 
synthase assay are shown in table 2.13.
Table 2.13 Citrate synthase assay reaction mixtures
Reagent Reference cuvette Test cuvette
200mM Tris (1.2g/50ml) pH8 500pl 500pl
lOmM Acetyl CoA 20pl 20pl
lOmM DTNB (4mg/ml) + KHCO3 20pl lOpl
Triton-XlOO lOpl lOpl
ddH20 440pi 430pl - xpl
Homogenised muscle or mitochondria - xpl
lOmM oxaloacetate (7mg/5mls) - lOpl
X = 5,10 or 15
The citrate synthase assay is performed as follows:
1. Select the citrate synthase assay on the Hitachi spectrophotometer. Wavelength = 412nm, 
temperature = 30°C.
2. Load 6 cuvettes (3 test: 3 reference) with the four common ingredients (Tris, Acetyl CoA, 
DTNB and Triton-XlOO) to each cuvette and pre-warm in the water bath.
3. To the reference cuvettes add 440pl of pre-warmed ddH20.
4. To the test cuvettes add 430pl - xpl of pre-warmed ddH20 and xpl of homogenised muscle 
or mitochondria.
5. Add 10 pi of oxaloacetate to the test cuvette and load both test and reference cuvettes into 
the spectrophotometer.
The spectrophotometer measures the change in absorbance between the two cuvettes 
producing an incline on the graph (figure 2.5).
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ABSORBANCE t
OAA added
TIME—>
Figure 2.5 Example of a graph for calculation of citrate synthase activity
•  •  •  « 3The M extinction coefficient of DTNB is 13.6 x 10 . The reaction rate is calculated as 
follows:
Rate (nmol/min/mol) =
Absorbance change
Time
13.6 x 10J
1000 1 
X -----------  X ------
pi sample 1000
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2.3.17 Culture of myoblasts from human muscle
On the day of the muscle biopsy the culture medium is made using the ingredients shown in 
table 2.14
Table 2.14 Myoblast culture medium
Ingredient Volume
Dulbecco’s modified Eagle’s medium + 
4.5g/l glucose (Sigma-Aldrich)
500ml
20% Fetal calf serum (GIBCO) 100ml
2pM Uridine 2ml
1 pM Sodium pyruvate 5ml
50pg Penicllin + 50pg streptomycin 2.5ml
A trypsinising solution is made by adding 4mls of trypsin to a 100ml bottle of versene 
(GIBCO).
A dissociation solution is made by dissolving 12,000 digestion units of collagenase (Sigma) 
and 40mg of bovine serum albumin (fraction V, fatty acid free) in lOmls of culture media. 
This is filter sterilised using a 0.2pm ministart filter before adding 3.2mls of trypsinising 
solution and finally making up the volume to 40mls using additional culture media.
Approximately 200mg of skeletal muscle from the biopsy is collected in lOmls of culture 
media. This is rinsed repeatedly in fresh media to remove excess blood and debris. The 
muscle is then transferred to a sterile 6cm plate and 5mls of pre-warmed dissociation solution 
(37°C) added. The muscle is carefully teased apart using sterile needles then incubated for 15 
minutes at 37°C. After this period 5mls of culture medium is added to halt the reaction before 
filtering through a cell strainer and centrifuging at l,000rpm for 10 minutes. The supernatant 
is discarded and the cells re-suspended in culture medium. Harvested aliquots of suspended 
cells are transferred to collagen coated plates and incubated at 37°C (figure 2.6).
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Figure 2.6 Cultured human myoblasts on a collagen coated plate
2.3.18 Passaging of cultured myoblasts
Passaging of the cultured myoblast is required once the cells become 70% confluent on the 
plate to prevent differentiation into mature cells. The media is removed and the plates washed 
with PBS. 1ml of trypsinising solution is added to the plate which is then incubated at 37°C 
for 3 minutes. Once the cells have become detached the reaction is halted by the addition of 
9mls of culture medium. This is then centrifuged at l,000rpm for 10 minutes and the 
supernatant discarded. The cells are then re-suspended in culture medium and split between 
two new plates.
2.3.19 Isolation of mitochondria from myoblasts by differential centrifugation
9ml of isolation buffer containing 0.2M sucrose, 0.13M sodium chloride and ImM Tris HC1 
(pH7.4) is added to a 1ml suspension of cultured myoblasts. The sample is then homogenized 
using a motor driven Potter homogeniser. This is then first centrifuged for 10 minutes at 
2,500rpm (500g) and the precipitate discarded. The supernatant is centrifuged for a further 15 
minutes at 9,500rpm (8,000g). The resulting supernatant is then discarded and the 
mitochondrial pellet re-suspended in isolation buffer.
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Chapter 3
CLINICAL CHARACTERISTICS OF 
AUTOSOMAL RECESSIVE HSP 
PATIENTS IN THE UK
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3.1 Introduction
The hereditary spastic paraplegias are a clinically and genetically diverse group of disorders. 
The clinical phenotype is classified as being pure when symptoms and signs are confined to 
those of a progressive spastic paraparesis. Posterior column dysfunction, with impaired 
proprioception and vibration sense, and bladder dysfunction are also permitted (Harding, 
1984). The phenotype is described as complicated in the presence of additional major 
neurological or other clinical features. A number of distinct clinical syndromes have been 
described such as the Troyer and Mast syndromes in the Old Order Amish population.
The diagnosis of HSP is relatively straightforward in the presence of a family history and a 
progressive spastic paraparesis as the predominant clinical feature. Alternative disorders that 
should be excluded, as proposed by the Hereditary spastic Paraplegia Working Group are 
summarised in table 3.1. This is by no means a comprehensive list but highlights some of the 
more common disorders which may be mistaken for HSP.
Clinical studies to date have mainly focused on the more prevalent autosomal dominant 
families. Reports on autosomal recessive families are most often in individual families from 
regions with high rates of consanguinity. Topaloglu and colleagues identified 23 Turkish 
families, all with early onset autosomal recessive HSP (Topaloglu et al., 1998). Of these 9 
families had a pure phenotype and 14 complicated phenotypes with cerbellar ataxia and 
cognitive impairment being the most frequent additional features. In the largest study to date 
Coutinho and colleagues assessed 106 affected individuals from 46 families with autosomal 
recessive HSP from Portugal and Algeria (Coutinho et al., 1999). In this series pure 
phenotypes were more prevalent than complicated forms (58.7% vs. 41.3%). They proposed a 
classification into five common phenotypes: (1) pure early onset, (2) pure late onset, (3) 
complicated with mental retardation, (4) complicated with mental retardation and peripheral 
neuropathy, and (5) complicated with cerebellar ataxia.
The aim of this study was to identify and characterise UK families with inheritance consistent 
with autosomal recessive HSP.
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Table 3.1 Differential diagnosis of HSP
Category Disorder Differentiating 
clinical features
Diagnostic
evaluation
Structural
abnormality
Am old-Chiari 
m alformations 
Cervical spondylotic 
m yelopathy
Spinal cord neoplasm
Ataxia
Upper limb
involvem ent,
radiculopathy
Pain, sensory signs,
asymmetric
involvem ent
MRI brain 
MRI spine
MRI spine
Inflammatory and 
degenerative disease
M ultiple sclerosis
Am yotrophic lateral 
sclerosis
Spinocerebellar
ataxias
Exacerbations and 
rem issions, optic 
neuritis 
Fasiculations, 
amyotrophy
Prominent ataxia
MRI, CSF  
examination, VEPs
EMG
Genetic testing
Leukodystrophy A L D /A M N
M LD
Krabbe
leukodystrophy
Cognitive
impairment,
peripheral
neuropathy
Psychom otor
regression, peripheral
neuropathy
Peripheral
neuropathy
MRI brain, VLCFAs
MRI brain, 
arylsulphatase
MRI brain, 
galactocerebrosidase
M etabolic disorders Subacute com bined  
degeneration
M itochondrial
cytopathies
Abetalipoproteinaem ia
Peripheral 
neuropathy, marked 
dorsal column  
involvem ent 
Short stature, retinitis 
pigm entosa, stroke­
like episodes 
Peripheral 
neuropathy
Vitamin B 12 levels
MRI brain, lactate, 
m uscle biopsy
Lipoprotein
electrophoresis
Infectious diseases Tertiary syphilis
Tropical spastic 
paraparesis 
HIV m yelopathy
Subacute course 
Subacute course 
Subacute course
VDRL, syphilis 
serology
HTLV-1 antibodies 
HIV antibodies
M iscellaneous D O PA -responsive
dystonia
D ium al variation Trial o f  levodopa
ALD = adrenoleukodystrophy; AMN = adrenomyeloneuropathy; MLD = metachromatic 
leukodystrophy; VLCFA = very long chain fatty acids, HTLV-1 = human T-cell lymphotropic 
virus type 1, HIV = human immunodeficiency virus (Adapted from Fink et al., 1996)
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3.2 Methods
Multi-regional ethical approval was obtained to carry out the clinical, genetic and biochemical 
studies on autosomal recessive and sporadic HSP cases. Proband patients were initially 
identified through an established HSP database stored at the Institute of Neurology in London 
and registered members of the UK familial spastic paraparesis support group. Additional 
patients were also subsequently identified through the British Neurological Surveillance Unit. 
Affected individuals and all available at risk family members were assessed including history 
and a full neurological examination.
Autosomal recessive inheritance was assumed when two or more siblings were affected with 
unaffected parents (on examination or by history when deceased) or one or more affected 
sibling in the presence of consanguinity. Diagnostic criteria were those of the Hereditary 
Spastic Paraplegia Working Group with alternative causes excluded as far as possible with 
MRI, electrophysiologic evaluation and biochemical testing in at least one affected member 
of each pedigree as documented in the medical records.
3.3 Results
A total of 20 UK families with autosomal recessive HSP, including 45 affected individuals 
were identified (figure 3.1). Age of onset ranged from 18 months to 62 years with two thirds 
of all cases presenting before the age of 20 (figure 3.2). Full details of the clinical 
characteristics of all affected individuals are presented in table 3.2. An overview of the 
prevalence of phenotypic characteristics is summarised in table 3.3.
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Figure 3.1 Pedigrees of UK families with autosomal recessive HSP
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Table 3.2 Clinical characteristics of all autosomal recessive HSP patients
Pedigree 1 1 1 1 1 1 2 2 3 3 3 4 4 5 5 6 6 7 7 8 8 9 10 10 11 11 12 12 12 13 14 14 15 15 15 16 16 17 17 18 18 19 19 20 20
Individual 2 3 4 5 7 8 1 2 1 2 3 1 2 1 2 1 2 1 4 1 2 1 2 3 1 2 1 2 5 1 3 4 1 2 3 1 2 1 2 1 2 1 2 1 2
Phenotpye p p p p p p c c c c c c c p p c c c c c c c p p c c c c c c c c p p p p p p p p p c c c c
Age  (years) 53 51 46 45 43 41 23 20 23 18 11 27 24 71 65 32 30 65 61 35 32 43 50 48 23 12 70 63 55 20 34 27 71 68 61 7 5 79 69 51 42 32 30 20 18
Age o f  onset (years) 8 40 9 14 20 14 16 14 8 14 10 13 16 62 50 21 20 20 16 14 14 5 14 19 11 8 40 52 45 14 21 14 30 50 41 2 2 58 56 33 32 2 2 5 3
Learning d i f f i c u l t i e s  + _ + + + + + „ . + + . -  + + - - - +  + - - - -  + + ...........................................................................................................
Dysarthria  + + + . . + + . -  + - -  - + + +  + + .  + ....................................................................................................................
Optic atrophy ...................................................................................................................+ +  + + ...........................................................................................................
Nystagmus  + . . .  +  + + + ................................................................................................................... + +
Ataxia  + + ........................................................................+ . . . . +  + + ....................................................................................................................................
Amyotrophy  + + +  + + +  + .  + .........................................................................................+ _ _
Extrapyramidal  + ....................................................................................................................
UL spasticity  + + +  + + . . +  + + ...........................................................................................................................................................................................
UL weakness
UL hyperreflexia + - + +  + + + + + + -  + - - + + + + + + + + + + -  - - - - - - - + .  .  .  _ _ _ .  _ + + _
Bladder dysfunction - + + + + - +  + + + -  + + + + + + -  - . +  + .....................................+ + .  _ + + + + _ .  +  .  .  _ + + _
Pes cavus .........................................................+ + ..............................................................................................+ .............................................................. + ....................................................................................................................
Syndacyly  + + .......................................................................................................................................................................................................................
LL spasticity + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + -|. + _(._|_
LL weakness + + + + + + + + + - - + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
LL hyperreflexia + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Extensor plantars + + + + + + + + + - + + + + + + + + + + + + + + + + .  + .  + + .  + + + + + + + + + + + + +
Impaired p a i n / t e m p ........................................................................................................................................................................ + .....................................................................................................................................................................  + _ _
Impaired vib/jps + + + + + + + + + -  - - .  +  + + . +  + .  .  + . .  .  .  +  + + + _ _ + + _  .  _ + _
Spatic gait + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Mobility I I S W S  I S I W I  I W W W W W S W W W W W S S S  I I S I I W I W W S  I I S S  I I I I S I
+ present, - absent, I independent, S sticks, crutches or frame, W wheelchairbound
Age of onset in autosomal recessive HSP
0-10 11-20 21-30 31-40 41-50 51-60 >60
Age (years)
Figure 3.2 Distribution of age of onset in UK autosomal recessive HSP patients
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Table 3.3 Summary of clinical features in all autosomal recessive HSP patients
CLINICAL FEATURE PREVELANCE
Pure phenotype 19/45 (42%)
Complicated phenotype 26/45 (58%)
Learning difficulties 14/45 (31%)
Dysarthria 12/45 (27%)
Optic atrophy 4/45 (9%)
Nystagmus 7/45 (16%)
Ataxia 6/45 (13%)
Amyotrophy 9/45 (20%)
Extrapyramidal features 1/45 (2%)
Upper limb spasticity 8/45 (18%)
Upper limb weakness 6/45 (13%)
Upper limb hyperreflexia 23/45 (51%)
Bladder dysfunction 25/45 (56%)
Pes cavus 4/45 (9%)
Syndactyly 2/45 (4%)
Lower limb spasticity 45/45 (100%)
Lower limb weakness 43/45 (96%)
Lower limb hyperreflexia 45/45 (100%)
Extensor plantar responses 41/45 (91%)
Impaired pain/temperature sensation 3/45 (7%)
Impaired vibration/joint position sense 22/45 (49%)
Spastic gait 45/45 (100%)
Independently mobile 18/45 (40%)
Mobile with stick/crutches/frame 12/45 (27%)
Wheelchair bound 15/45 (33%)
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In total, 7 families, including 19 affected individuals, were classified as having a pure HSP 
phenotype. Of these 47% demonstrated upper limb hyperreflexia, 53% reported symptoms of 
bladder dysfunction and 68% had signs of posterior column dysfunction with impaired 
vibration and joint position sense. Variability in age of onset and disease severity was noted 
within affected members of the same family.
The remaining 13 families including 26 affected members were classified as having 
complicated HSP phenotypes with a variety of additional neurological features. Syndacyly of 
the second and third toes of both feet was the only significant non-neurological associated 
feature identified in two affected siblings from one family. Learning disability as documented 
by an educational psychologist, consultant neurologist or formal IQ testing was the most 
common additional feature, present in 31% of all patients. Progressive cognitive decline was 
often suggested although confirmation of this in the form of serial testing could not be 
established from patient records. Dsyarthria, either spastic or cerebellar in nature, was also a 
frequent finding occurring in 27% of cases. Marked distal amyotrophy, as distinguished from 
disuse atrophy, was present in 20% of cases and invariably accounted for any documented 
upper limb weakness. Cerebellar ataxia occurred in 13% of cases and was usually associated 
with nystagmus, although in one family two affected siblings with congenital nystagmus and 
no cerebellar signs were identified. Optic atrophy and extrapyramidal features were relatively 
rare.
3.4 Discussion
A total of 20 UK families with autosomal recessive HSP were identified for clinical and 
genetic studies. The use of the database at the Institute of Neurology included only patients 
who had been seen at the National Hospital for Neurology and DNA stored for research 
studies. This is likely to have excluded large numbers of patients from outside the south of 
England. The additional use of the family register from the familial spastic paraparesis 
support group helped extend the search although only a proportion of patients diagnosed with 
HSP join the support group and not all complete the survey. The British Neurological 
Surveillance Unit has provided useful assistance in identifying patients with rare neurological 
disorders from around the country although not all consultant neurologists participate in this
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and it does not attract attention of clinicians working in other areas such as paediatrics and 
clinical genetics. Some patients may also have already been involved in research studies into 
HSP and therefore been reluctant to become involved with another group. It is, therefore, not 
possible to comment on overall prevalence in the UK although such cases are undoubtedly 
rare.
The majority of autosomal recessive HSP families studied (65%) had complicated phenotypes 
with a variety of additional neurological features. This is higher than previously reported 
surveys (Topaloglu et al., 1998; Coutinho et al., 1999). The fact that a significant proportion 
of cases were contacted through the Institute of Neurology database may have biased this 
observation, as more straightforward pure cases may not have been referred for a specialist 
neurogenetic opinion.
The most frequent additional neurological features were learning disability, ataxia and 
amyotrophy. This is similar to previously reported studies (Topaloglu et al., 1998; Coutinho et 
al., 1999). However, these complicating features seemed to occur variably in combination 
both between and within families. Therefore, the division into distinct phenotypic subtypes as 
suggested by Coutinho and colleagues seems less clear-cut in our group of patients and is 
unlikely to be helpful in planning genetic linkage studies.
Two thirds of all cases had a disease onset before the age of 20 years which is typical of 
autosomal recessive disorders. However a number of late onset cases were identified and a 
variation of age of onset of up to 32 years in members of one family supports the fact that 
additional environmental or genetic factors influence the disease. However, autosomal 
dominant inheritance with incomplete penetrance or X-linked inheritance in families where 
only males are affected cannot be entirely excluded.
Overall, the methods used identified a useful cohort of patients with autosomal recessive HSP 
for further genetic studies. Further collaboration between neuroscience centres around the UK 
and the establishment of a national database of HSP families would assist in the generation of 
more accurate epidemiological data and recruitment of patients for genetic research.
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Chapter 4
A CLINICAL AND GENETIC STUDY 
OF SPG5A LINKED AUTOSOMAL 
RECESSIVE HSP
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4.1 Introduction
In 1994 Hentati and colleagues studied a group of five unrelated Tunisian families with 
autosomal recessive HSP (Hentati et al., 1994). The phenotype in all affected individuals was 
an early onset pure form of HSP with bladder dysfunction and mild posterior column sensory 
impairment. Using a genome wide linkage analysis approach they mapped a 32.8cM region in 
the pericentromeric area of chromosome 8 co-segregating with the disease in four of the five 
families with a maximum combined LOD score of 8.77 at marker D8S260. This was the first 
autosomal recessive HSP locus to be identified and subsequently designated SPG5A. The 
family excluded from linkage to this locus was clinically indistinguishable from the others 
demonstrating genetic heterogeneity for this form of HSP.
In 1999, Coutinho and colleagues reported one further consanguineous Algerian family from 
a total of 23 Algerian and Portuguese pedigrees in which linkage to the SPG5 A locus could 
not be excluded, with a maximum LOD score of 1.96 at marker D8S1797 (Coutinho et al., 
1999). Although this was not useful in refining the existing locus it was postulated that 
SPG5A linked AR HSP was likely to be rare and may be restricted to the North African 
population.
From the 20 UK autosomal recessive HSP families identified only pedigree 1 (figure 3.1) was 
of significant size for independent linkage analysis. The phenotype in this family was of a 
pure early onset form of HSP, similar to those characterised by Hentati and colleagues linked 
to the SPG5A locus. Linkage analysis was therefore undertaken in this family using markers 
spanning the SPG5A locus. Linkage to SPG5 A was confirmed with peak two point LOD 
scores of 3.26 at 0 = 0 at markers D8S260 and D8S601. Further marker saturation analysis 
allowed refinement of the existing locus to a 23.6cM interval between markers D8S1051 and 
D8S1807 with a maximum multipoint LOD score of 4.84 between markers D8S1833 and 
D8S285. Screening of several candidate genes from within this region did not identify any 
pathogenic mutations. Muscle biopsy analysis from two affected individuals did not 
demonstrate any evidence of oxidative phosphorylation defects.
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4.2 Material and methods
4.2.1 Subjects
The family was one of twenty autosomal recessive HSP kindred identified through an 
established database of HSP patients (pedigree 1 in figure 3.1). The parents were Caucasian 
first cousins. All living members were independently examined by two neurologists. All gave 
consent to participate in the study which received multi-regional ethical approval.
4.2.2 Genotyping and linkage analysis
Genomic DNA was extracted from whole blood using standard protocols (section 2.3.1). 
Linkage to the SPG5A locus was initially tested using the polymorphic microsatellite markers 
D8S260 and D8S601. Amplified PCR products were size fractionated by electrophoresis 
using 8% polyacrylamide gels (section 2.3.4) and visualised by silver staining (section 2.3.5). 
Additional marker saturation analysis at the SPG5 A locus was performed using established 
markers based on information from the Marshfield map of chromosome 8.
Pairwise LOD scores were calculated using MLINK and multipoint LOD scores using 
HOMOZ under the assumption of equal allele frequencies and equal male and female 
recombination rates. Disease inheritance was presumed to be as an autosomal recessive trait 
with complete penetrance and an allele frequency of Kf4. For the generation of multipoint 
LOD scores the family was deconstructed to facilitate computational efficiency.
4.2.3 Muscle biopsy analysis
Open muscle biopsy was performed under local anaesthetic from the left vastus lateralis 
muscle in two of the affected siblings 11:3 and 11:7. Muscle was analysed for standard 
histological and histochemical reactions including sequential cytochrome c oxidase (COX) 
and succinate dehydrogenase (SDH) reactions. Muscle samples from both patients and seven 
age matched controls were prepared and assayed as previously described for mitochondrial 
complex I, II/III, IV and citrate synthase (sections 2.3.13-2.3.16). Respiratory chain complex 
enzyme activities were all corrected for citrate synthase.
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4.2.4 Mutation detection
Primers were designed to amplify the entire coding regions and splice junctions of five genes 
from within the SPG5A locus; AP3M2, LOC138051, ATP6VH1, SDCBP and TRAM 
(appendix 2). For each gene DNA was used from the mother (an obligate carrier) and one 
affected individual. 50pl PCR reactions were performed under optimised conditions (section
2.3.2). Purified PCR products were sequenced using BIGDYE (Applied Biosystems) and 
analysed on the ABI 3100 genetic analyser (sections 2.3.10 and 2.3.11).
4.3 Results
4.3.1 Clinical analysis
The family was of English ancestry. The parents were first cousins with six of their eight 
children were affected. Individual 1:1 died age 74 of carcinoma of the pancreas and by history 
had no evidence of gait disturbance or other neurological disorder. Individual 11:2 was 
examined as part of this study. Aged 83 she had no abnormal neurological signs. The main 
clinical findings of affected individuals are summarised in table 4.1. The phenotype observed 
was a pure form of HSP with four of the six affected members having some degree of 
additional bladder dysfunction. All affected individuals also demonstrated evidence of 
posterior column sensory impairment with varying degrees of diminished vibration sensation 
and proprioception. Significant variability in age of onset (8-40 years) and rate of disease 
progression was noted among affected individuals.
Initial investigations in the oldest affected sibling (11:2) included a normal MRI of the brain 
and spinal cord. A myelogram and CSF examination were also normal. Cortical evoked 
responses were absent from the legs and bilaterally delayed from the arms. Visual and 
brainstem evoked potentials were normal. More recently patient 11:3 was re-investigated due 
to the later age of onset and milder phenotype. MRI of the brain and spinal cord was normal 
apart from the incidental finding of a Rathke’s pouch cyst. EMG and nerve conduction studies 
were normal. Posterior tibial somatosensory evoked potentials were bilaterally absent. A full 
biochemical screen including white cell enzymes and very long chain fatty acids failed to 
identify any alternative cause for a spastic paraparesis.
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Table 4.1 Clinical characteristics of affected individuals
Family member
Characteristic 11:2 11:3 11:4 11:5 11:7 11:8
Age at examination (years) 53 51 46 45 43 41
Age of onset (years) 8 40 9 14 20 14
Bladder dysfunction 
Upper limbs:
~ - + ++ + +
Spasticity - - - - - -
Weakness - - - - - -
Hyperreflexia + - + + + +
Posterior column sensory impairment 
Lower limbs:
~ “ - “
Spasticity +++ ++ +++ +++ +++ +++
Ankle clonus - - + + + +
Weakness + + ++ +++ ++ +
Hyperreflexia + + + + + +
Posterior column sensory impairment + + + + + +
Extensor plantar reflexes + + + + + +
Current mobility I I F W F I
+ = present (+mild, -H-moderate, +++severe), - = absent.
I = Independent, F = Requires walking frame, W = Wheelchair bound.
4.3.2 Muscle biopsy analysis
Muscle biopsy samples from both affected individuals demonstrated varying degrees of 
denervation changes. There was a substantial variation in fibre size with an excess of type 1 
fibres. Both samples showed numerous small atrophic, angulated fibres which were 
predominantly type lib (figure 4.1). No ragged red fibres were seen. Oxidative stains were 
within normal limits in patient 11:3. In patient 11:7 no COX negative fibres were present 
although there were some SDH positive fibres . A small patch of inflammatory infiltration 
was also noted, although this is unlikely to be of any significance (figure 4.2). Mitochondrial 
respiratory chain analysis from both patient muscle samples did not demonstrate a significant 
reduction in mitochondrial function (figure 4.3).
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Figure 4.1 ATPase stained muscle biopsy from patient 11:3 showing small angulated type lib 
fibres
Figure 4.2 Gomori trichrome stained muscle biopsy from patient 11:7 showing a small patch 
of inflammatory infiltration
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4.3.3 Linkage analysis
Analysis of microsatellite markers spanning the SPG7, SPG11, SPG14, SPG15 and SPG 20 
loci all generated LOD scores of <-2, excluding linkage. In contrast, two point LOD scores 
for both D8S260 and D8S601 (LOD score 3.26 at 0 = 0) confirmed linkage to the SPG5A 
locus. Haplotype analysis of additional surrounding markers is shown in figure 4.4. A region 
of homozygosity co-segregating with the disease in all affected individuals was established 
between markers D8S589 and D8S543. Multipoint LOD scores across the region were 
significantly positive with a maximum score of 4.84 between markers D8S1833 and D8S285 
(figure 4.5). Loss of homozygosity occurred at markers D8S1051 and D8S1807, reducing the 
SPG5A locus interval to 23.6cM.
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D8S532
D8S1051
D8S589
D8S1815
D8S601
D8S538
D8S524
D8S1833
D8S28S
D8S260
D8S510
D8S1797
D8S543
D8S1807
D8S1776
11:1 11:2 11:3 11:4 11:5 11:6 11:7 11:8
D8S532 2 i 2 n 1 2tl i 2 n 1 2 n 1 2 l 2I1 1 2f1D8S1051 1 2 3 2 3 2 3L 2 3L 2 1 2 3L 2 3L
D8S589 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2
D8S1815 2 1 1 1 1 1 1 1 1 1 2 1 1 1 1
D8S601 3 1 1 1 1 1 1 1 1 1 3 1 1 1 1
D8S538 3 1 1 1 1 1 1 1 1 1 3 1 1 1 1
D8S524 2 1 1 1 1 1 1 1 1 1 2 1 1 1 1
D8S1833 2 1 1 1 1 1 1 1 1 1 2 1 1 1 1
D8S285 3 1 1 1 1 1 1 1 1 1 3 1 1 1 1
D8S260 3 1 1 1 1 1 1 1 1 1 3 1 1 1 1
D8S510 3 2 2 2 2 2 2 2 3 2 2
D8S1797 3 1 1 1 1 1 1 1 1 1 3 1 1 1 1
D8S543 3 1 1 1 1 1 1 1 1 1 3 1 1 1
D8S1807 1 2 1 2 1 2 M 2 1 I  l a  t,2 1 2 1 2D8S1776 2 2 3 U 2 3 U 2 3 LI 2 3 U 3 1 3 U 2 3 U 2
Figure 4.4 Haplotype construction in autosomal recessive HSP family for chromosome 8 markers demonstrating a 
region of homozygosity in all affected individuals between markers D8S589 and D8S543. Bracketed haplotypes are 
inferred
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Figure 4.5 Multipoint analysis of all chromosome 8 markers generating a maximum LOD 
score of 4.84 between markers D8S1833 and D8S285
Of the remaining 19 ARHSP kindred SPG5A linkage was excluded in all but two small 
families, in which the number of affected individuals was insufficient to generate statistically 
significant LOD scores.
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4.3.4 Mutation screening
Direct sequencing of the entire coding regions and splice junctions of five candidate genes 
from within the refined SPG5A locus with protein products predicted to play a role in 
intracellular transport or mitochondrial function (AP3M2, LOCI38051, ATP6VH1, SDCBP 
and TRAM) failed to identify any pathogenic mutations.
4.4 Discussion
Linkage of pure autosomal recessive HSP to a 32.8cM region on chromosome 8 (SPG5A) 
was initially established by Hentati and colleagues in four out of five Tunisian families 
(Hentati et al., 1994). A further Algerian family subsequently has also shown probable 
linkage to this region (Coutinho et al., 1999). We have identified the first English autosomal 
recessive HSP family conclusively linked to the SPG5A locus, providing evidence that it is 
not confined to one ethnic group and may account for a significant proportion of cases 
worldwide.
Clinical features of affected individuals in this family were similar to those previously 
described with a pure HSP phenotype. Again, posterior column sensory loss was apparent 
along with symptoms of bladder dysfunction in four of six affected individuals suggesting a 
possible common phenotype for SPG5A linked HSP. However, within the family the age of 
onset ranged from 8 to 40 years of age with variability in disease severity and progression 
suggesting additional environmental or genetic factors may affect the course of the disease.
There have been limited studies of muscle pathology and mitochondrial function in HSP 
(Hedera et al., 2000; Santorelli et al., 2000b; Piemonte et al., 2001; McDermott et al., 2002). 
Muscle biopsies from patients with paraplegin mutations have shown evidence of 
mitochondrial dysfunction, including ragged red fibers, SDH-positive and COX-negative 
fibers, although in less severely affected individuals only scattered COX-negative fibers may 
be seen (Casari et al. 1998; McDermott et al 2001). Impairment of oxidative phosphorylation 
has also been reported in a small number of unlinked autosomal dominant and recessive HSP 
cases (Santorelli et al., 2000b; Piemonte et al., 2001; McDermott et al., 2002). The muscle 
biopsy in patient 11:7 contained some SDH positive fibers although there were no other 
indications of mitochondrial dysfunction. This was supported by normal respiratory chain
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function assays in both samples. The small patch of inflammatory infiltration seen in patient 
11:7 is of uncertain significance, although it is unlikely this reflects the underlying 
pathogenesis of the disease, particularly as it was not seen in the second affected patient.
Genetic linkage analysis in this family has enabled a moderate refinement of the SPG5A locus 
to a 23.6cM interval at chromosome 8ql l.l-q21.2. These findings should prompt 
investigation of further autosomal recessive HSP families from diverse ethnic groups to assess 
linkage to SPG5A. Muglia and colleagues have subsequently reported a further potential 
refinement of the SPG5A locus using combined LOD scores in four small autosomal 
recessive HSP pedigrees, although in view of the increasingly broad genetic heterogeneity of 
the disorder this method raises doubts that for each individual family apparent linkage may 
simply have been observed due to chance (Muglia et al., 2004). The confirmed locus therefore 
remains large, containing over 250 established genes or partial transcripts.
The fact that muscle biopsy analysis in two affected individuals from this family did not show 
any histological or biochemical evidence of oxidative phosporylation defects means that a 
nuclear encoded mitochondrial protein similar to paraplegin is unlikely to play a pathogenic 
role. The possible function of other recently identified HSP genes in cellular trafficking 
dynamics highlights proteins with this functionality as candidates from within the refined 
SPG5A locus. Sequencing of 5 candidate genes; AP3M2, LOCI38051, ATP6VH1, SDCBP 
and TRAM, from within the critical interval failed to identify any coding sequence mutations. 
This means that these candidates are unlikely to play a causative role in SPG5 A linked HSP 
although mutations in upstream promoter regions or intronic sequence cannot be excluded. 
The search for further SPG5A linked families to narrow down the critical interval will help to 
rationalise the candidate gene screening approach to identify the causative gene for this form 
of HSP.
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Chapter 5
A CLINICAL, GENETIC AND 
BIOCHEMICAL STUDY OF SPG7 
MUTATIONS IN HEREDITARY 
SPASTIC PARAPLEGIA
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5.1 Introduction
SPG7 was the first autosomal recessive HSP gene to be characterised. Located on 
chromosome 16, it comprises 17 exons spanning approximately 52 kb. The protein product, 
paraplegin, consists of 795 amino acids and localises to mitochondria. It was originally found 
to share its closest amino acid sequence homology with the yeast mitochondrial 
metalloproteases Afg3, Real and Ymel (Casari et al., 1998; Settasatian et al., 1999). These 
proteins are members of the AAA protein superfamily (ATPase associated with diverse 
cellular activities) which are found widely in both prokaryotic and eukaryotic cells and play 
an important role in a variety of cellular activities including cell division, transcription, 
organelle biogenesis, vesicle transport and enzyme assembly (Patel and Latterich, 1998). 
More specifically, yeast mitochondrial ATPases are known to possess both proteolytic and 
chaperone-like activities at the inner mitochondrial membrane where they are involved in the 
assembly and degradation of proteins in the respiratory chain complex (Pearce, 1999). 
Mutation of these genes in yeast induces a respiratory chain defect due to a block in the 
assembly of the subunits into functional enzymes (Paul and Tzagoloff, 1995). Subsequently a 
number of additional human genes encoding proteins highly homologous to paraplegin such 
as AFG3L1, AFG3L2 and YME1L1 have been discovered (Kremmidiotis et al., 2001; Banfi 
et al., 1999; Coppola et al., 2000). The precise function of paraplegin and related proteins in 
humans remains uncertain.
At the time of this work four SPG7 mutations had been described resulting in either pure or 
complicated HSP phenotypes. Following linkage to 16q24.3 in a large consanguineous Italian 
family with a variable complicated phenotype (De Michele et al., 1998), Casari and 
colleagues discovered a 9.5kb deletion corresponding to the last five exons of the SPG7 gene 
(Casari et al., 1998). Muscle biopsy analysis from two severely affected individuals from this 
family revealed characteristic changes of mitochondrial oxidative phosphorylation defects 
including ragged-red fibres, cytochrome oxidase negative (COX) and succinate 
dehydrogenase (SDH) positive fibres. Electron microscopy confirmed an accumulation of 
abnormal mitochondria containing paracrystalline inclusions in a “parking lot” pattern. 
However, in two less severely affected individuals only a few scattered COX negative fibres 
were seen. Two additional frameshift mutations, a two base pair deletion in exon 6 in a small 
Italian family with pure HSP and a single base insertion in exon 17 in a French HSP kindred
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with a complicated phenotype including optic, cortical and cerebellar atrophy were also 
identified. Both families were consanguineous and homozygous for the mutation (Casari et 
al., 1998). Most recently, McDermott and colleagues detected a heterozygous nine base pair 
deletion in exon 11 of SPG7 in a father and son both affected by a spastic paraparesis 
suggesting a possible autosomal dominant mode of inheritance in this family (McDermott et 
al., 2001).
The aim of this study was to screen a large cohort of autosomal recessive and sporadic HSP 
cases from Great Britain to estimate the prevalence of SPG7 mutations in this population and 
further characterise the nature of mitochondrial dysfunction in affected individuals.
5.2 Materials and methods
5.2.1 Subjects
The 20 autosomal recessive HSP kindred previously described and a further 29 sporadic 
patients with no family history, in whom alternative causes for a spastic paraplegia had been 
excluded, were identified through an established database of British HSP patients and the 
British Neurological Surveillance Unit. All individuals gave informed consent to participate 
in the study, which received multi-regional ethical committee approval.
5.2.2 Genotyping and linkage analysis
Genomic DNA was extracted from whole blood using standard protocols (section 2.3.1). 
Linkage to the SPG7 locus was investigated in the 20 autosomal recessive HSP families using 
the polymorphic microsatellite markers D16S413, D16S3023 and D16S303. Amplified PCR 
products were size fractionated by electrophoresis using 8% polyacrylamide gels (section 
2.3.4) and visualised by silver staining (section 2.3.5). Pairwise LOD scores were calculated 
using MLINK under the assumption of equal allele frequencies and equal male and female 
recombination rates. Disease inheritance was presumed to be as an autosomal recessive trait 
with complete penetrance and an allele frequency of 10"4.
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5.2.3 Mutation detection
18 pairs of primers were designed, based on chromosome 16 draft sequence data, to amplify 
the coding region and flanking splice junctions of all 17 exons of the SPG7 gene. 50pl PCR 
reactions were performed under optimised conditions (table 5.1).
Table 5.1 Primers and conditions for SPG7 PCR reactions
Exon Forward primer Reverse primer Anneal
temp.
°C
mM
MgCl
PCR 
product 
size (bp)
1 5’ ATCACGCAGGCGCGGCTTTCAG 3' 5' CT GGGCCTT AC AG AGC AGA 3' 60 1.5 270
2 5' AGTCTGC ATTGCTTT GGT ACT 3' 5' TAGCTGAGGCGATAAGTGTG 3' 57 1.5 228
3 5’ GGAGTAC ACTGTT GTCCT GT 3’ 5' ACAGAAATGTAAAGACATCCAG 3’ 55 1.5 226
4A 5' AAGCTCTGGATGTCGCCCGT 3' 5' AGGAAATGCTGCCTCCGCTG 3’ 57 1.5 193
4B 5' GCGGTTGTCATGAGCCTCCT 3' 5' CTCACTCTCACAGGCTGCCA 3’ 57 2.0 241
5 5' GACTGTAGGGTTGCTCGTCT 3' 5' CAGATTACAAAGCCAAGTTAGG 3' 55 1.5 260
6 5' TTGGAAGCCTGCGTCTGTCA 3' 5' GTATTCAGCAAACACAAACCAG 3' 57 1.5 225
7 5’ CTGGCATCGTGCTGCTGATT 3' 5' CCCTTCTGGGAGAGGAGGA 3’ 57 1.5 257
8 5' AGTGTTGCATTGTCTGCTGC 3’ 5' ATGTGTGAAAGGAGCCAGGT 3’ 57 2.0 252
9A 5' CCTT GGT GT AG AACTTT GTCT 3’ 5' TGTTGGAGAAGCCGGACATG 3’ 55 1.5 221
9B 5' GCATCGTCTACATCGATGAG 3' 5' CCTGTTCTGAAAGACATCGG 3' 55 1.5 187
10 5' TCCCTCCTGTGTCCTGAAGG3' 5' CCAGACCACTCAGAGCGAGT 3' 57 1.5 283
11 5' ACCTGTGGCAGTAACTAGGT 3' 5' GCCTTGATGCTGTTTGCGCA 3' 57 1.5 211
12 5' CTCTT AAGCCCT GAT AGC AG 3' 5' TC ACCTCTC AAT ACCT GCCT 3' 55 2.0 252
13 5' GTCTCGAACTCCTGTCCTCA 3' 5* AGTCAGCTACAGACACAGGC 3' 60 1.5 300
14 5' ACGGAGACCTCTTAGTCCCA 3' 5' C ATGGC AT GC ACT GG AAC AG 3* 55 2.0 321
15 5' ACTGCTCTGCGCCTGCAGT 3’ 5’ CCTTGTGTGGTAGACCCA 3' 57 1.5 294
16 5' TCTGTGCTTTGGTGCTGGAG 3’ 5’ ACCGTGGGTGCTGTGTGGA 3’ 57 1.5 206
17 5’ ACATGCATATGCCTGTTCTTT 3’ 5' CTCAGCTGAAAAGCAACTCAG 3' 55 1.5 312
Single strand conformation polymorphism (SSCP) analysis was performed using 0.6% 
Mutation Detection Enhancement (MDE) gels run at 4-10°C for 10-16 hrs to achieve 
optimum separation of the strands (section 2.3.12). Mobility shifts were characterised by 
direct sequencing of purified PCR products using BIGD YE (Applied Biosystems) and 
analysed on the ABI 3100 genetic analyser (section 2.3.11).
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5.2.4 Muscle biopsy analysis
Open muscle biopsies were performed under local anaesthetic from vastus lateralis in two 
patients with SPG7 mutations. Muscle was analysed for standard histochemical reactions 
including sequential cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) 
reactions through the clinical service at the Royal Free Hospital. Muscle samples from both 
patients, four additional patients with autosomal recessive HSP in whom linkage to SPG7 had 
been excluded and 19 age-matched controls were also prepared and assayed for mitochondrial 
complex I, II/III, IV and citrate synthase as previously described (sections 2.3.12-2.3.16). 
Activities were corrected for citrate synthase. Respiratory chain complex activity was also 
measured in mitochondrial fragments isolated from cultured myoblasts by differential 
centrifugation from both patients and nine age-matched controls.
5.3 Results
5.3.1 Genotyping and linkage analysis
Linkage to the SPG7 locus was excluded in 14 of the 20 autosomal recessive HSP kindred 
(LOD score <-2). The remaining 6 families were not excluded due to the small pedigree size 
or uninformative markers. One affected individual from each of these families along with the 
29 sporadic spastic paraplegia cases were therefore screened for SPG7 mutations.
5.3.2 Mutation detection
Following initial SSCP analysis and sequencing of all mobility shifts, a total of 12 
heterozygous sequence changes were identified in the coding regions of the SPG7 gene. Four 
were previously reported polymorphisms. Three other conserved sequence changes, 120G—»A 
(G40G), 1816 C—>T (G605G) and 2283G—>A (Q761Q), were also subsequently identified in 
control samples defining them as novel polymorphisms. The remaining five coding sequence 
changes were not identified in 200 control chromosomes supporting these as pathogenic 
mutations. An additional 7 intronic polymorphisms were also identified in patient and control 
samples during sequencing. A summary of SPG7 polymorphisms and their relative 
frequencies in patient and control chromosomes is presented in table 5.2.
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Table 5.2 Frequency of SPG7 polymorphisms in patients and controls
Location Nucleotide
change
Predicted protein 
change
Patient
Chromosomes 
(n = 70)
Control 
Chromosomes 
(n= 100)
Exon 1 120G—>A G40G 1 1
Intron 4 IVS4 + 12C—>T - 36 56
Intron 7 IVS7 + 5G—>A - 2 3
Intron 7 IVS7 + 17G—*C - 2 2
Intron 7 IVS7 + 38G—>A - 3 5
Intron 10 IVS10+ 19G-*A - 2 5
Exon 11 1507A—>G T503A 2 6
Exon 11 1529C—*T A510V 1 4
Intron 12 IVS12 +13C—>T - 1 4
Intron 13 IVS13 +45G—>C - 14 31
Exon 14 1816C—>T G605G 0 1
Exon 15 2063G—>A R688Q 5 24
Exon 17 2283G—>A Q761Q 2 2
Exon 17 2292C—>T I764I 2 4
In total, six SPG7 mutations were identified, five of which were novel (table 5.3). Two 
sporadic spastic paraplegia patients (1 and 2) were compound heterozygotes, each possessing 
two different mutations. A further sporadic patient (3) initially appeared to carry only a single 
heterozygous mutation, the 9 base pair deletion in exon 11 (1450-1458del9) that had 
previously been associated with possible autosomal dominant inheritance. Direct sequencing 
of all the remaining exons in this patient revealed a second sequence change in exon 15, 
2026C—>T (F676L), which had not produced a visible mobility shift on SSCP under any 
conditions tested. A new pair of primers containing the sequence change in the first base of 
the reverse primer were therefore designed and PCR under optimised conditions successfully 
amplified the patient DNA but none of 100 control samples, supporting this as the second 
mutation in this patient.
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Table 5.3 SPG7 mutations detected
Patient Location Nucleotide change Predicted protein change
1 Exon 1 28G—»T A10S
Exon 13 1729G—>A G577S
2 Exon 8 1057-1085del29 Frameshift 353-384X385
Exon 13 1715C—»T A572V
3 Exon 11 1450-1458del9 E,R,R484-486del
Exon 15 2026T—>C F676L
5.3.3 Clinical characteristics of patients with SPG7 mutations
SPG7 mutations were associated with variably complicated HSP phenotypes in all three 
patients (table 5.4). Age of onset ranged from 11 to 19 years with slowly progressive 
deterioration. All demonstrated increased tone in all four limbs, more prominent in the legs, 
with relatively preserved power. Patients 2 and 3 both had marked cerebellar ataxia with 
associated dysarthria and cerebellar eye signs. None of the patients had signs of optic atrophy.
MRI brain scans in patients 2 and 3, who had ataxia, showed cerebellar atrophy (figure 5.1). 
Two small areas of periventricular high T2 signal lesions of uncertain significance were also 
noted in patient 2. MRI appearances of the spinal cord were normal in all three patients. 
Electromyogram (EMG), nerve conduction studies (NCS) and visual evoked responses in 
patients 2 and 3 were also normal.
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Table 5.4 Clinical characteristics of patients with SPG7 mutations
Patient 1 2 3
Age (years) 17 51 42
Sex M F M
Age of Onset (years) 11 14 19
Dysarthria + + -
Nystagmus - + +
Bladder dysfunction - - +
Upper Limb
Spasticity + + +
Weakness - - -
Ataxia - + +
Hyperreflexia + + +
Sensory impairment - - -
Lower Limb
Pes cavus + +
Spasticity + + +
Weakness - + +
Ataxia - + +
Hyperreflexia + + +
Sensory impairment - + -
Plantar reflexes t r t t t t
Gait Spastic Spastic-ataxic Spastic-ataxic
Functional status Independent Requires stick Independent
EMG/NCS Not done Normal Normal
MRI Brain Normal Periventricular T2 Cerebellar
MRI Spinal cord Normal
hyperintensity. 
Cerebellar atrophy 
Normal
atrophy
Normal
M = male, F = female, + = present, - = absent, f f = bilaterally extensor
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Figure 5.1 Axial T2 MRI brain in patient 3 showing cerebellar atrophy
Both parents of patient 3 had a normal neurological examination as part of this study. The 
parents of patient 1 were not available, but had previously been examined and felt to be 
normal. The parents of patient 2 were also not available (mother died, father declined to be 
involved) but neither had any neurological or gait abnormalities by history.
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5.3.4 Muscle biopsy analysis
Muscle biopsies from patients 2 and 3 both showed changes of denervation with limited 
reinnervation. In each case fibre typing showed a marked excess of type 1 fibres with 
numerous small, atrophic, angulated fibres, predominantly type II. No ragged-red fibres were 
seen and, although there were a few scattered COX negative fibres throughout the biopsies, 
oxidative stains, including SDH, were considered within normal limits for the age of the 
patients.
Analysis of mitochondrial respiratory chain function in muscle from patients 2 and 3 is shown 
in figure 5.2. Compared to controls, citrate synthase corrected activities for complex 1 and 
complex II/III fell below the mean control range in both patients, while complex IV activity 
appeared relatively preserved. A similar picture was apparent when the two SPG7 mutation 
patients were compared to other autosomal recessive HSP patients in whom linkage to SPG7 
had been excluded, with complex I and complex II/III activities falling below mean controls. 
However, due to the small sample size in this group confidence intervals for the mean control 
activities were large and the differences not significant (table 5.5). Respiratory chain function 
assays on mitochondrial fractions isolated from cultured myoblasts in both SPG7 mutation 
patients also demonstrated a reduction in citrate synthase corrected complex I activity outside 
the standard error for mean control rates, although complex II/III and complex IV activities 
were within the normal range (figure 5.3).
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Mitochondrial respiratory chain complex activities
in muscle
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Figure 5.2 Respiratory chain complex activity corrected for citrate synthase in homogenised 
muscle
* Complex IV activity x 101
* Control data expressed as mean +/- 95% Cl
Mitochondrial respiratory chain activities in 
myoblast mitochondrial fractions
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Figure 5.3 Respiratory chain complex activity corrected for citrate synthase in myoblast 
mitochondrial fractions
* Complex IV activity x 101
* Control data expressed as mean +/- 95% Cl
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Table 5.5 Mitochondrial respiratory chain complex activities corrected for citrate synthase in 
SPG7 mutation patients, non-SPG7 autosomal recessive HSP patients and controls
Complex I Complex II/III Complex IV
Muscle
Patient 2 0.182 0.132 0.018
Patient 3 0.15 0.14 0.017
Controls 0.227 ± 0.037 0.217 ±0.032 0.019 ±0.004
Non-SPG7 HSP 0.185 ±0.085 0.211 ±0.116 0.017 ±0.116
Myoblast
Patient 2 0.09 0.27 0.025
Patient 3 0.044 0.28 0.018
Controls 0.158 ±0.046 0.288 ± 0.046 0.027 ±0.011
± 95% Confidence Interval
5.4 Discussion
Since the discovery of SPG7 as the first gene responsible for autosomal recessive HSP only 
four mutations, each in separate families, have been reported (Casari et al., 1998; McDermott 
et al, 2001). Three occurred in consanguineous pedigrees possessing homozygous mutations, 
while the most recently reported heterozygous nine base pair deletion in exon 11 (1450- 
1458del9) was found in the father and son from a family in which possible autosomal 
dominant inheritance was suggested. We have identified six SPG7 mutations, in three 
apparently sporadic HSP cases. All were compound heterozygous for two separate mutations. 
A remarkably similar phenotype with prominent cerebellar ataxia was observed in two of 
these cases. No mutations were identified in any of the six autosomal recessive HSP patients 
from families in whom linkage to the SPG7 locus could not be excluded. The distribution of 
the mutations identified in SPG7 is shown in figure 5.4
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PI = patient 1, P2 = patient 2, P3 = patient 3.
Figure 5.4 Schematic representation of the SPG7 gene showing functional domains and sites 
of mutations
The two missense mutations in patient 1 occur in highly conserved functional domains. The 
A10S mutation in exon 1 results in the substitution of a hydrophobic to hydrophilic amino 
acid residue in the leader peptide of paraplegin, which is essential for targeting of the protein 
to mitochondria. These short amino acid sequences at the N-terminal of nuclear encoded 
mitochondrial proteins need to form a basic, amphipathic helix in order to fulfil this function 
(Lithgow, 2000). The introduction of a hydrophilic amino acid residue into the leader peptide 
is therefore predicted to disrupt the mitochondrial localisation of paraplegin. The second 
mutation, G577S, is situated within the conserved zinc-binding motif (HESGH) providing 
further evidence for the functional significance of this domain in paraplegin.
In patient 2, the missense mutation in exon 13 (A572V), results in an amino acid substitution 
two residues before the zinc binding domain. Although both are small non-polar, hydrophobic 
amino acids, modelling of the mutant protein with the prediction program GOR4 fhttp://npsa- 
pbil.ibcp.fr/cgi-bin/secpred gor4.pl) showed an altered conformation in the region of the 
zinc-binding domain from an alpha helix, random coil, alpha helix pattern to an extended
P2 P3 P2 PI P3
384X385 E,R,R484-486del A572V G577S F676L
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strand. This alteration in secondary structure is likely to disrupt the functional activity of this 
domain. The second mutation in patient 2, a 29 base pair deletion in exon 8 (1057- 
1085del29), is within the AAA cassette involving part of the highly conserved ATP binding 
motif. It causes a frameshift with a premature stop codon at residue 385, predicted to result in 
a truncated protein.
The first mutation identified in patient 3 was the nine base pair deletion in exon 11 (1450- 
1458del9), previously reported as a possible autosomal dominant mutation (McDermott et al., 
2001). This is within the AAA cassette, resulting in the loss of three amino acids (E,R,R484- 
486del). In patient 3 our SSCP analysis also failed to identify a second mutation and it was 
only by direct sequencing of the remaining SPG7 exons that a further sequence change, 
2026C—►T (F676L) was detected. This was confirmed as a mutation by allele specific 
oligonucleotide analysis in 200 control chromosomes.
Neurological examination of the parents of patient 3, both in their 70’s and asymptomatic, 
was entirely normal. Sequencing of the two exons in both parents confirmed the mother 
carried the nine base pair deletion in exon 11 (figure 5.5) and the father the missense mutation 
in exon 15. In this case the 1450-1458del9 clearly acts in an autosomal recessive manner with 
a combination of two heterozygous mutations required to produce the disease phenotype. The 
second mutation F676L did not occur in an obvious functional domain within paraplegin. It 
results in substitution of leucine for phenylalanine and this change was not detected in 200 
control chromosomes implying it is likely to be pathogenic.
1 2  3
Figure 5.5 8% PAGE gel showing normal SPG7 exon 11 in lane 1 (father) and 9 base pair 
deletions in lanes 2 (mother) and 3 (patient 3)
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Histological analysis of muscle from two patients with confirmed SPG7 mutations failed to 
demonstrate the previously reported morphological changes associated with oxidative 
phosphorylation impairment, although both our patients were still ambulatory and are likely 
to have been less severely affected than previous cases. The absence of these features on 
muscle biopsy therefore cannot be used to exclude SPG7 as the cause of the disease. The only 
consistent finding was of denervation changes with an excess of type I fibres which probably 
reflects longstanding spasticity.
Mitochondrial respiratory chain activities in muscle from patients 2 and 3 did, however, show 
a reduction in complex I and complex II/III function, when corrected for citrate synthase, 
compared to controls. Similar results were obtained when respiratory chain complex activities 
in muscle were compared to other patients with autosomal recessive HSP in whom SPG7 
mutations had been excluded, suggesting that this effect may not simply reflect the effect on 
muscle of longstanding spasticity and reduced mobility. However, due to the small number of 
non-SPG7 autosomal recessive HSP patients differences between the two groups did not 
reach statistical significance.
A previous study of respiratory chain function in muscle from HSP patients included two 
patients with autosomal recessive HSP, in whom SPG7 mutations had been excluded 
(Piemonte et al., 2001). One of these had characteristic histological changes associated with 
oxidative phosphorylation impairment and both had isolated complex I deficiencies. A recent 
study of mitochondrial function in HSP patients in whom both SPG4 and SPG7 mutations had 
been excluded also demonstrated a reduction in both complex I and complex IV activities 
(McDermott et al, 2003), suggesting respiratory chain defects may be common to more than 
one form of autosomal recessive HSP.
The pattern of complex I-III deficiency in skeletal muscle is reminiscent of the pattern of 
defect found in cardiac tissue from patients with Friedrich’s ataxia (FRDA) (Bradley et al., 
2000). In FRDA deficiency of frataxin is thought to result in abnormal iron-sulphur cluster 
formation in respiratory chain proteins, leading to oxidative stress and damage. This pattern 
of complex I-III deficiency is also seen, for example, in the SOD2 knockout mouse (Melov et 
al., 1999). It is therefore possible that the pattern of respiratory chain defect in the muscle 
from patients with SPG7 mutations may represent excess free radical mediated damage. The
i l l
fact that only a defect in complex I activity was observed in myoblasts may simply represent 
the accumulation of oxidative damage in a fixed as opposed to dividing tissue.
Subsequently, Atorino and colleagues have also demonstrated complex 1 deficiency in 
cultured fibroblasts from two of the original patients with the homozygous 9.5kb deletion in 
SPG7 (Atorino et al., 2003). In addition, they demonstrated that paraplegin forms a complex 
with a homologous protein AFG3L2 at the inner mitochondrial membrane, which was found 
to be abnormal in the HSP fibroblasts. The increased sensitivity to oxidative stress was found 
to be reversed by the exogenous expression of wild-type paraplegin suggesting that the 
complex I deficiency may directly contribute to the process of neurodegeneration.
Overall SPG7 mutations appear to be a relatively rare cause of HSP, identified in only 3/49 
(6%) of patients studied. This figure, however, should be regarded as a minimum estimate as 
it is likely that SSCP may have failed to detect all mutations. In addition, this study 
demonstrates that the SPG7 locus is highly polymorphic which means that SSCP would not 
be an efficient tool for screening for mutations and direct sequencing may be preferable. 
Elleuch and colleagues recently screened a total of 136 individuals with both pure and 
complicated autosomal recessive HSP using a combination of denaturation high-performance 
liquid chromatography and direct sequencing (Elleuch et al., 2006). They identified 47 
sequence variations in the SPG7 gene including 6 mutations, 27 polymorphisms and 14 
changes with uncertain effects. Of these only one case had compound heterozygous mutations 
which were definitely causative. The phenotype in this family was also complicated with 
cerebellar ataxia. 20 further families were found to have a single heterozygous mutation not 
found in a large control population. Of these four were predicted to produce highly defective 
proteins suggesting that they were indeed pathogenic. It is therefore possible that large scale 
deletions, intronic or promoter sequence mutations may be causative in these cases. Overall 
this study supports a frequency of SPG7 mutations causing autosomal recessive HSP in 
around 5% of cases.
Unlike many of the more common forms of HSP it is hoped that the underlying pathogenesis 
involving mitochondrial dysfunction associated with SPG7 mutations may make these cases 
more amenable to therapeutic interventions than other forms of the disease. A mouse model 
for paraplegin-associated HSP has also now been developed (Ferreirinha et al., 2004). 
Paraplegin deficient mice manifest progressive motor impairment with similar pathological
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evidence of axonal degeneration, morphologically abnormal mitochondria and impaired 
respiratory chain function as seen in human patients. Recently, using a gene therapy approach, 
the intamuscular delivery of paraplegin through an adenoassociated virus vector has been 
shown to rescue some of the axonal changes seen in paraplegin deficient mice (Pirozzi et al., 
2005). Again, this offers hope that similar techniques may be developed for treatment in 
human patients. However, gene therapy using a variety of vectors remains in the early stages 
for treating human disease and is limited by both safety issues and the ability to target 
delivery of the gene to the appropriate areas, in this case the central nervous system. The 
mouse model does though provide future opportunities for testing drug treatments based on 
neuroprotection or improving mitochondrial respiratory chain function. Further studies are 
required to determine the precise function of paraplegin in human mitochondria in health and 
disease in order to facilitate the development of potentially disease modifying treatments for 
this type of HSP.
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Chapter 6
SPG3A MUTATION SCREENING 
IN ENGLISH FAMILIES WITH 
EARLY ONSET AUTOSOMAL 
DOMINANT HSP
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6.1 Introduction
In 1993 Hazan and colleagues mapped the first locus for autosomal dominant HSP 
(SPG3A) to chromosome 14q (Hazan et al., 1993). Linkage to this region was 
excluded in further autosomal dominant HSP kindred confirming the genetic 
heterogeneity of the disease. Following further refinement of the critical interval,
Zhao and colleagues screened for mutations in a number of candidate genes in three 
large SPG3A linked families (Zhao et al., 2001). They identified three separate 
pathogenic mutations in a gene encoding a novel protein with significant homology to 
the dynamin family of GTPases, which they named atlastin. The mutations were all 
situated within the N-terminal region, resulting in the alteration of amino acids in the 
conserved GTPase domain.
Sequencing of the SPG3A gene in a further 10 early onset autosomal dominant HSP 
kindred, in which linkage analysis had not been performed, identified a further two 
families in whom all affected individuals possessed the same R239C mutation found 
in one of the original linked pedigrees. Although these families were not apparently 
related a distant founder effect could not be excluded (Zhao et al., 2001). Muglia and 
colleagues subsequently identified a further SPG3A mutation in an additional 
autosomal dominant HSP family (Muglia et al., 2002). Again this was situated within 
the N-terminal region. All the families with SPG3A mutations were noted to have an 
early onset pure HSP phenotype.
In this study we screened 12 English autosomal dominant HSP families with an early 
onset pure form of the disease to assess the frequency of mutations in this population.
6.2 Patients and methods
12 autosomal dominant HSP families with an uncomplicated phenotype and age of 
onset less than 12 years were identified from an existing database of HSP patients. 
Approval for genetic studies in HSP was obtained from the multi-regional ethics 
committee and all participants gave informed consent. DNA from index cases from 
each of the 12 families had previously been screened for spastin mutations using a 
combination of single stranded conformation polymorphism (SSCP) analysis and
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sequencing of any motility shifts (Proukakis et al., 2003). No sequence variations 
were identified in the SPG4 gene in any of these cases.
DNA was extracted from whole blood using standard techniques (section 2.3.1). The 
14 exons and flanking sequences of the SPG3A gene were amplified by the 
polymerase chain reaction (PCR) using the primers and conditions described 
previously (Zhao et al., 2001). Sequencing of purified PCR products on both strands 
was performed using the Big Dye Terminator kit (Applied Biosystems) according to 
manufacturer’s protocols and analysed on the ABB 100 genetic analyser (section 
2.3.11). Single strand conformation polymorphism (SSCP) analysis was performed 
using 0.6% Mutation Detection Enhancement (MDE) gels run at 10°C for 14 hrs to 
achieve optimum separation of the strands (section 2.3.12).
6.3 Results
Direct sequencing identified a heterozygous C and T at nucleotide 884 of the atlastin 
full length cDNA resulting in the previously described R239C mutation in the index 
case from one autosomal dominant HSP family. Co-segregation of the disease with 
the mutation in all affected members was demonstrated by SSCP analysis of the exon 
7 PCR product (figure 6.1) and subsequently confirmed by direct sequencing (figure
6.2). The age of onset of the disease in this family was identical in all affected 
individuals at 3 years of age with insidious disease progression and increasing 
disability over many years. The main clinical characteristics of all affected individuals 
studied are summarised in table 6.1. No further SPG3A mutations were identified in 
any of the 14 exons or flanking splice sites in affected individuals from the remaining 
11 families.
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Figure 6.1 Early onset autosomal dominant HSP family with SSCP analysis of exon 7 
showing different motility patterns in affected and unaffected individuals
0 120 130 140 150
G G T G C C A A A T T  CTTGG A A A A A C G C CT C A AG G T TTG TT AG ATJ
90 100 110 120
G G T G C  C A A A T T C T T G G  AAA A AH G C C TC A AG G T T T GT TA G AT A
Figure 6.2 Representative SPG3A sequences from normal and affected individuals. 
The arrow indicates the heterozygous C and T at nucleotide 884 in an affected 
individual
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Table 6.1 Clinical characteristics of affected individuals carrying the R239C mutation
Family member
Characteristic 1:2 11:1 11:2 11:3 111:1 111:2
Age at examination (years) 62 40 35 33 14 11
Age of onset (years) 3 3 3 3 3 3
Bladder dysfunction - - - - - -
Upper limbs:
Spasticity _ _ _ _ _ _
Hyperreflexia - - - - - -
Lower limbs:
Spasticity _ ++ +++ +++ +++ +++
Ankle clonus - + + + + +
Weakness +++ ++ ++ ++ + +
Hyperreflexia - + + + + +
Sensory impairment - - - - - -
Extensor plantar responses + + + + + +
10m walk time (seconds) 19 13 14 15 12 11
Walking aid + - - - - -
- = absent, + = present (+ mild, ++ moderate, +++ severe)
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6.4 Discussion
The identification of the R239C mutation in exon 7 of the SPG3 A gene is the first to 
be confirmed in an English autosomal dominant HSP family, highlighting a 
widespread prevalence. This particular mutation is the most frequently occurring 
SPG3 A mutations so far described, suggesting either a commonly occurring new 
mutation or founder effect from a common ancestral mutation.
The phenotype observed in this family was of a uniformly early onset uncomplicated 
HSP, with all affected members developing gait disturbance from the age of 3 years. 
This appears to be the commonest phenotypic presentation with SPG3 A mutations 
and when there is little or no disease progression cases may be mistaken for spastic 
diplegic cerebral palsy (Rainier et al., 2006). However, later onset patients have been 
reported, in one case associated with the same mutation that was found in an early 
onset family (Sauter et al., 2004). A complicated phenotype with axonal neuropathy 
has also been described (Scarano et al., 2005).
Despite the early onset in this family there was clear evidence of insidious disease 
progression with worsening lower limb weakness and increasing disability with time, 
suggesting an underlying neurodegenerative rather than neurodevelopmental process. 
However, the phenotype associated with SPG3A mutations does appear overall to be 
less severe than those frequently seen with other forms of autosomal dominant HSP 
where patients may be wheelchair bound after prolonged disease duration (Reid et al., 
1999). In this family the disease demonstrated complete penetrance with no 
apparently asymptomatic individuals carrying the mutation, as has been observed in 
other forms of autosomal dominant HSP (Patel et al., 2001). Only one family with 
SPG3 A mutations demonstrating incomplete penetrance has so far been described 
(D’Amico et al., 2004).
Overall SPG3A mutations were identified in affected individuals from only 1/12 (8%) 
early onset uncomplicated autosomal dominant HSP families from the UK, indicating 
that even within this specific group of autosomal dominant HSP patients SPG3 A 
mutations appear to be rare. Patients had been previously screened for spastin 
mutations using a combination of single stranded conformation polymorphism
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(SSCP) analysis and sequencing of any motility shifts although it is possible that 
mutations may have been missed using this screening method and large scale 
deletions of the spastin gene, which have recently been found to be as common as 
point mutations (Depienne et al., 2007) would not be detected with this approach. It is 
therefore still possible that some of these families may harbour undetected spastin 
mutations causing an early onset HSP phenotype.
Subsequent studies screening for SPG3A mutations in early onset, spastin negative, 
autosomal dominant HSP patients from different populations have reported a much 
higher prevalence. Sauter and colleagues identified SPG3A mutations in 38% of such 
cases (Sauter et al., 2004), while Durr and colleagues demonstrated a similar 
prevalence of 39% among European and African families (Durr et al., 2004). This 
suggests that either the frequency of SPG3 A mutations varies significantly between 
populations or that due to the smaller numbers studied in our group SPG3 A mutations 
were underrepresented.
The precise function of atlastin in humans and mechanism by which mutations cause 
disease remain unclear. Dynamins, the proteins most closely associated with atlastin, 
are known to play a role in a wide variety of vesicle trafficking events (McNiven et 
al., 2000). The atlastin protein is localised to the Golgi apparatus predominantly in 
brain, where it is enriched in pyramidal neurons in the cerebral cortex and 
hippocampus (Zhu et al., 2003). Recently using confocal and electron microscopies, 
Zhu and colleagues have found that atlastin is highly enriched in vesicular structures 
within axonal growth cones and axonal branch points in cultured cerebral cortical 
neurones, suggesting a possible functional role for atlastin in axonal development 
(Zhu et al., 2006). To support this notion knockout of atlastin expression in these 
neurones was found to reduce the number of neuronal processes and impair axon 
formation and elongation during development (Zhu et al., 2006).
Two separate groups have also recently identified that atlastin binds with spastin 
which is a microtubule severing ATPase involved in axonal transport suggesting that 
there may be disruption to a common molecular pathway responsible for axonal 
growth and maintainace underlying these forms of HSP (Sanderson et al., 2006;
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Evans et al., 2006). Further studies into the function of atlastin and consequences of 
mutations should enhance our understanding of the pathogenesis of the disease.
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Chapter 7
A NEW LOCUS FOR 
AUTOSOMAL RECESSIVE HSP, 
SPG26, MAPS TO CHROMOSOME
12pll.l-12ql4
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7.1 Introduction
At the time of this work nine autosomal recessive HSP loci had been identified and 
causative mutations found in three genes; SPG7 (paraplegin), SPG20 (spartin) and 
SPG21 (maspardin) [Casari et al., 1998, Patel et al., 2002; Simpson et al., 2003].
SPG7 was the first autosomal HSP gene to be characterised. The protein product of 
the SPG7 gene, paraplegin, is a member of the AAA protein superfamily (ATPase 
associated with diverse cellular activities). Paraplegin localises to the mitochondria 
and is highly homologous to a number of yeast mitochondrial metalloproteases , 
which are known to possess both proteolytic and chaperone-like activities at the inner 
mitochondrial membrane where they are involved in the assembly and degradation of 
proteins in the respiratory chain complex (Pearce, 1999). SPG7 mutations may result 
in either pure or complicated HSP phenotypes. Muscle biopsy analysis of patients 
with SPG7 mutations may show histological evidence of mitochondrial dysfunction 
and recently biochemical studies have shown specific defects in mitochondrial 
respiratory chain function (Casari et al., 1998; McDermott et al., 2001).
Mutations in the SPG20 and SPG21 genes have so far only been identified in the Old 
Order Amish population in association with well-characterised complicated HSP 
phenotypes, the Troyer and Mast syndromes (Patel et al., 2002; Simpson et al., 2003). 
The protein product of SPG20, spartin, contains a MIT domain and is thought to play 
a role in cellular trafficking (Ciccarelli et al., 2003). Similarly maspardin, the product 
of the SPG21 gene, has been shown to localise to transportation vesicles and may play 
a role in protein transportation or sorting (Simpson et al., 2003).
The remaining autosomal recessive HSP loci have been mapped to chromosomes 
8ql l.l-q21.2, SPG5A (Hentati et al., 1994; Wilkinson et al., 2003); 15ql3-ql5,
SPG11 (Martinez Murillo et al., 1999; Shibasaki et al., 2000), 3q27-q28, SPG14 
(Vazza et al., 2000), 14q22-q24, SPG 15 (Hughes et al., 2001); Iq24-q32, SPG23 
(Blumen et al., 2003); 13ql4, SPG24 (Hodgkinson et al., 2002) and 6q23-q24.1, 
SPG25 (Zortea et al., 2002).
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We identified a large consanguineous Kuwaiti family with autosomal recessive HSP, 
complicated by distal amyotrophy, dysarthria and intellectual impairment for further 
genetic analysis.
7.2 Materials and methods
7.2.1 Subjects
A large consanguineous family comprising of five affected and seven unaffected 
siblings with a complicated HSP phenotype were identified through the medical 
genetics services in Kuwait. The parents were first cousins and of Bedouin ancestry. 
All individuals gave informed consent to participate in the study, which received 
ethical committee approval.
7.2.2 Genotyping and linkage analysis
Genomic DNA was extracted from whole blood using standard protocols (section
2.3.1). Genome wide linkage analysis, using parents and affected individuals only, 
was performed with the ABI linkage marker set (version 2) with an ABI 3100 genetic 
analyser and Genotyper software (version 3.7) [sections 2.3.6-2.3.9J. Marker 
saturation analysis was performed using microsatellite markers based on information 
from the Marshfield genetic map of chromosome 12. Amplified PCR products were 
size fractionated by electrophoresis using 8% polyacrylamide gels (section 2.3.4) and 
visualised by silver staining (section 2.3.5). Multipoint LOD scores were calculated 
using GENEHUNTER (version 2.1) under the assumption of equal allele frequencies 
and equal male and female recombination rates. Disease inheritance was presumed to 
be as an autosomal recessive trait with complete penetrance and an allele frequency of 
10"4. The pedigree was deconstructed to aid computational efficiency.
7.2.3 Sequencing of the KIF5A gene
The 28 exons and flanking splice junctions of the KIF5A gene were amplified using 
the primers and reaction conditions described previously (Reid et al., 2002). 
Sequencing of purified PCR products was performed using the Big Dye Terminator 
kit (Applied Biosystems) according to manufacturer’s protocols and analysed on the 
ABB 100 genetic analyser (section 2.3.11).
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7.3 Results
7.3.1 Clinical analysis
The clinical characteristics of this family were initially reported by Farag and 
colleagues in 1994 (Farag et al., 1994). The family were subsequently re-assessed as 
part of this study by two independent neurologists in Kuwait (E Samilchuck and R 
Khan) and additional investigations carried out. A uniform early onset of disease 
between 6 and 11 years of age was noted. At the time of examination all affected 
individuals had signs of a progressive spastic paraparesis with distal amyotrophy in 
both upper and lower limbs. Four of the five were dysarthric. All demonstrated mild 
to moderate intellectual impairment with reduced verbal and performance IQ, 
although it is unclear whether this represents progressive cognitive decline, static 
learning disability or secondary to other factors associated with their physical 
disability. The clinical characteristics of affected individuals are summarised in table
6.1. Neurological examination of the parents and remaining siblings was 
unremarkable. Routine biochemical studies and neurophysiological testing including 
nerve conduction velocities and EEG were within normal limits. MRI of the brain in 
one of the affected individuals was unremarkable.
Table 7.1 Clinical characteristics of affected individuals
Affected individual 1 2 3 4 5
Age at examination 42 39 36 30 22
(years)
Age of onset (years) 6 6 6 6 11
Dysarthria +++ +++ +++ +++ -
Distal amyotrophy +++ + +++ +++ +++
Lower limb spasticity +++ +++ +++ ++ +
Ankle clonus + + + - -
Lower limb hyperreflexia +++ +++ +++ +++ +
Plantar response t t tt tt i f i f
Gait Spastic-ataxic Spastic Spastic Spastic Spastic
Emotional lability + +++ + +++ -
IQ
Verbal 55 55 52 48 73
Performance 61 72 73 73 64
- absent, +  mild, + +  moderate, + + +  severe, f t  bilaterally extensor, f f  bilaterally flexor
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7.3.2 Genotyping and linkage analysis
Following the genome wide scan a region of homozygosity was identified on 
chromosome 12 flanked by markers D12S345 and D12S326. Marker saturation 
analysis demonstrated a 22.8cM region of homozygosity co-segregating with the 
disease in all affected individuals flanked by markers D12S59 and D12S1676 (figure
7.1). Multipoint LOD scores across the region were significantly positive with a 
maximum score of 5.1 between markers D12S1686 and D12S1702 (figure 7.2).
A database search of the region identified approximately 400 known or predicted 
genes including KIF5A, in which a missense mutation (A767G) has previously been 
described in a family with an uncomplicated autosomal dominant form of HSP. Direct 
sequencing of all 28 exons and splice junctions of the KIF5A gene in parents and 
affected individuals did not reveal any pathogenic mutations.
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Figure 7.1 Haplotype construction in the Bedouin family for chromosome 12 markers demonstrating a region of 
homozygosity in all affected individuals flanked by markers D12S59 and D12S1676
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Figure 7.2 Multipoint LOD scores for markers situated across the SPG26 locus, 
flanked by markers D12S59 and D12S1676
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Figure 7.3 Representation of the SPG26 locus showing the position of KIF5A and 
other potential candidate genes
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Table 7.2 Potential candidate genes and predicted protein functions from within the 
SPG 12 locus
GENE
SYMBOL
PROTEIN
PRODUCT
FUNCTION
KIF21A Kinesin family 
member 21A
Belongs to a family of kinesin motor proteins. Neurons 
use kinesin and dynein microtubule-dependent motor 
proteins to transport essential cellular components along 
axonal and dendritic microtubules. Mutations in KIF5A 
cause a form of autosomal dominant HSP (SPG 10)
CNTN1 Contactin 1 A member of the immunoglobulin superfamily. It is a 
glycosylphosphatidylinositol-anchored neuronal 
membrane protein that functions as a cell adhesion 
molecule. It may play a role in the formation of axon 
connections.
TUBA3 Alpha 3 tubulin Part of the tubulin superfamily of microtubule 
constituents. Expressed predominantly in differentiated 
neuronal cells.
MCRS1 Microspherule 
protein 1
A subset of the p78 proteins. Escorts fragile X mental 
retardation protein-containing silent ribonucleoparticles 
from the nucleus and nucleolus to the somato-dendritic 
compartment where it might participate in neuronal 
translation regulation.
ATP5B ATP synthase 
beta polypeptide
A subunit of mitochondrial ATP synthase. Mutations in 
the nuclear encoded mitochondrial protein paraplegin 
cause a form of autosomal recessive HSP
DCTN2 Dynactin 2 A subunit of dynactin, which binds to both microtubules 
and cytoplasmic dynein. It is involved in a diverse array 
of cellular functions, including ER-to-Golgi transport, 
movement of lysosomes and endosomes, spindle 
formation, chromosome movement, nuclear positioning 
and axonogenesis. Mutations in dynactin 1 are associated 
with a familial form of motor neurone disease.
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7.4 Discussion
Linkage to a 22.8cM region on chromosome 12 has been established in this 
consanguineous Kuwaiti family with a complicated HSP phenotype. Although this 
region contains the KIF5A gene in which a missense mutation has previously been 
described in a single family with a pure autosomal dominant form of HSP (Reid et al., 
2002), the fact that no pathogenic mutations were identified in affected individuals in 
any of the exons, or flanking splice junctions of KIF5A in affected individuals from 
this pedigree is strongly supportive of a further causative gene in this region. The 
different mode of inheritance and complicated phenotype with dysarthria, distal 
amyotrophy and cognitive impairment in our family would further support this 
hypothesis, although upstream promoter sequence or intronic mutations and large 
scale deletions of KIF5A cannot be entirely excluded.
We have therefore concluded that this region on chromosome 12p 11.1-12q 14 
represents a novel locus for autosomal recessive HSP, SPG26. This study should 
prompt the investigation of additional autosomal recessive HSP families for linkage to 
this region on chromosome 12, which may aid in the refinement of this currently large 
locus. Ribai and colleagues have recently identified a consanguineous Spanish family 
with a complicated HSP phenotype including ataxia and congenital cataracts 
putatively linked to the SPG26 locus (Ribai et al., 2005). Following genome wide 
linkage analysis in this family they identified a region of homozygosity flanked by 
markers D12S1617 and D12S1702 which overlaps the SPG26 locus and, although 
maximal multipoint LOD scores only reached 2.53, would potentially reduce the 
candidate interval slightly from 23cM to 20cM.
Based upon the proposed functions of the genes so far identified in the various forms 
of HSP, a variety of different underlying pathogenic mechanisms have been proposed 
including the disrupted development of the corticospinal tracts, mitochondrial 
dysfunction and defects in subcellular transportation and sorting processes (Crosby 
and Proukakis, 2002; Reid, 2003). A number of potential candidate genes have been 
identified based on these principles (table 7.2). This may provide an alternative 
approach to screening while the locus remains so large.
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Following the report of the SPG26 locus four further new HSP loci have been 
described, demonstrating the marked genetic heterogeneity of the condition. Meijer 
and colleagues mapped a pure autosomal recessive HSP family to 10q22.1-q24.1 
(SPG27), which partially overlaps the existing SPG9 locus (Meijer et al., 2004). 
Bouslam and colleagues mapped a further pure autosomal recessive HSP family from 
Morocco to chromosome 14q21.3-q22.3 (SPG28) and excluded mutations in the 
SPG3 A gene located within this interval (Bouslam et al., 2005). Orlacchio and 
colleagues identified linkage to chromosome Ip31.1-p21.1 (SPG29) in a Scottish 
family with autosomal dominant HSP complicated by deafness and hiatus hernia 
(Orlacchio et al., 2005). They failed to identify any pathogenis mutations in the SNX7 
gene encoding one of the sorting nexin proteins involved in various aspects of 
intracellular transport. Most recently, Klebe and colleagues have mapped a family of 
Algerian origin with a complicated form of autosomal recessive HSP including mild 
ataxia and a sensory neuropathy to chromosome 2q37.3. They excluded linkage to this 
locus in 10 additional European and North African families with autosomal recessive 
HSP (Klebe et al., 2006).
The identification of the causative gene in SPG26 and theses additional HSP loci 
should hopefully enhance our understanding of the pathogenic mechanisms 
underlying this heterogeneous disorder.
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Chapter 8
GENERAL DISCUSSION
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8.1 Identification of HSP families
The aim of this project was to study the clinical, genetic and biochemical features of 
autosomal recessive HSP, predominantly in the UK population. In total 20 families, 
comprising of 46 affected individuals, with inheritance consistent with autosomal 
recessive HSP were identified. One of the main limiting factors was the ascertainment 
of sufficient numbers of patients with a rare neurological illness and, in particular, 
families with a significant number of affected individuals for linkage analysis. The 
now well-established FSP support group in the UK has helped to facilitate this process 
through a family database and the neurological disease surveillance unit established 
by the Association of British Neurologists provides an additional resource for the 
study of rare neurological disorders. However, further co-operation between research 
groups around the UK and beyond, such as the Clinical and Genetic Analysis of 
Cerebellar Ataxias and Spastic Paraplegias study group (SPATAX) will be vital in 
coordinating future research efforts.
8.2 Phenotypes in autosomal recessive HSP patients
Of the 20 autosomal recessive families identified, only one was of sufficient size for 
linkage analysis. Neurological assessment of affected individuals in this group 
confirmed the clinical heterogeneity of the disorder, with widespread variability in 
phenotypes between and even within families. Overall the majority of autosomal 
recessive HSP patients (58%) were found to have a complicated phenotype with a 
variety of additional neurological features. The commonest additional neurological 
features were learning difficulties (31%), dysarthria (27%) and distal amyotrophy 
(20%). Due to the marked genetic heterogeneity of autosomal recessive HSP 
combining the different small families for genome wide linkage analysis would only 
be feasible if a common rare phenotype were shared between them to suggest an 
allelic association.
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8.3 Confirmation and refinement of the SPG5A locus
Linkage analysis in the large consanguineous autosomal recessive HSP family (figure
3.1, pedigree 1) confirmed linkage to the previously described SPG5A locus (Hentati 
et al., 1994). The phenotype of a pure, early onset form of HSP was identical to those 
described in the original study. This represented the first family outside of Africa 
conclusively linked to the SPG5A locus. Marker saturation of the area allowed 
refinement of the critical interval for SPG5A to a 23.6cM region on chromosome 8q. 
Sequencing of 5 candidate genes (AP3M2, LOCI38051, ATP6VH1, SDCBP and 
TRAM) from within the critical interval failed to identify any coding sequence 
mutations. This means that these candidates are unlikely to play a causative role in 
SPG5A linked HSP although mutations in upstream promoter regions, intronic 
sequence or large scale deletions cannot be excluded. The fact that muscle biopsy 
analysis in two affected individuals from this family did not show any histological or 
biochemical evidence of oxidative phosporylation defects means that a nuclear 
encoded mitochondrial protein such as paraplegin is unlikely to play a pathogenic 
role. The search for further SPG5A linked families to narrow down the critical 
interval will help to rationalise the candidate gene screening approach to identify the 
causative gene for this form of HSP.
8.4 SPG7 mutation screening in autosomal recessive and sporadic 
HSP patients
Of the 20 autosomal recessive HSP families linkage to the SPG7 locus was excluded 
in 14, including the large family linked to the SPG5A locus. One affected individual 
from each of the remaining families along with 29 sporadic spastic paraplegia cases 
were screened for SPG7 mutations using a combination of SSCP and sequencing of 
mobility shifts. Using this approach two of the sporadic cases were found to be 
compound heterozygotes for novel SPG7 mutations. In a third sporadic case SSCP 
identified only the previously reported the 9 base pair deletion in exon 11 (1450- 
1458del9) that had previously been associated with possible autosomal dominant 
inheritance. Direct sequencing of all the remaining exons in this patient revealed a 
second sequence change in exon 15, 2026C—>T (F676L), which had not produced a 
visible mobility shift on SSCP under any conditions tested. The sensitivity of SSCP in
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detecting sequence changes under optimised conditions has been reported at up to 
95% (Miterski et al., 2000), although as in this case mutations may not be apparent in 
the form of motility shifts and therefore it is possible that the frequency of SPG7 
mutations in this group may have been higher than detected. In particular the high 
number of polymorphisms in the SPG7 gene may mask additional changes. Direct 
sequencing of the entire coding region and splice junctions remains the most effective 
method of identifying mutations, although is more expensive and time consuming.
8.5 Genotype-phenotype correlations with SPG7 mutations
Both pure and complicated HSP phenotypes have previously been reported in 
association with SPG7 mutations (Casari et al., 1998; McDermott et al., 2001). Our 
three patients with compound heterozygote SPG7 mutations all had variable 
complicated phenotypes with two of the three showing marked cerebellar ataxia. The 
variability in phenotype may be explained by the functional domains of the paraplegin 
protein affected by the mutations, with both the ataxic patients having large deletions 
disrupting the AAA cassette. Additional genetic and environmental factors may also 
contribute to the phenotypic manifestations.
8.6 Oxidative phosphorylation defects with SPG7 mutations
Muscle biopsies were obtained from two of the patients with SPG7 mutations. Unlike 
in previous reports (Casari et al., 1998; McDermott et al., 2001) no clear histological 
changes of oxidative phosphorylation defects were identified in our patients. This is 
relatively common in neurodegenerative disorders associated with mutations in 
nuclear encoded mitochondrial proteins (Orth and Schapira 2001) and therefore 
histological changes in muscle biopsies cannot be reliably used to detect patients with 
SPG7 mutations. Mitochondrial respiratory chain function assays on muscle tissue 
confirmed a reduction in complex I-III activity, compared to controls, in both patients 
demonstrating for the first time the biochemical abnormality underlying this form of 
HSP. This pattern of complex I-III deficiency has also been reported in Friedrich’s 
ataxia and the SOD2 knockout mouse (Melov et al., 1999). It is therefore possible that 
the pattern of respiratory chain defect in the muscle from patients with SPG7
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mutations may represent excess free radical mediated damage. The fact that only a 
defect in complex I activity was observed in myoblasts may simply represent the 
accumulation of oxidative damage in a fixed as opposed to dividing tissue. Complex 1 
deficiency has also subsequently been demonstrated in cultured fibroblasts from 
patients with SPG7 mutations to support these findings (Atorino et al., 2003).
8.7 SPG3A mutation screening in early onset pure autosomal 
dominant HSP
Following the identification of the SPG3A gene, encoding the novel protein atalstin, 
in autosomal dominant HSP families (Zhao et al., 2001) we reviewed the database for 
autosomal dominant cases in which spastin mutations had previously been excluded. 
In view of the fact that all the affected individuals originally described had an early 
onset pure form of HSP, the screening process was refined to include only those with 
an onset before the age of 12 years and an uncomplicated phenotype. DNA from one 
affected member of the 12 families selected was sequenced for mutations in the entire 
coding sequence and adjacent splice junctions of the SPG3A gene. The previously 
described R239C mutation was the only pathogenic mutation identified in one of the 
twelve families. Overall this indicated that in the UK population studied, even within 
the early onset uncomplicated cases SPG3A mutations were relatively uncommon but 
provided further evidence of a commonly occurring mutation site. This could 
represent either a mutation hotspot or a founder effect from a commonly occurring 
ancestral mutation. This theory could be tested by haplotype analysis of families 
across the world with the R239C mutation.
Subsequent studies have identified a number of additional SPG3 A mutations have 
been described in different populations and expanded the SPG3A phenotype (Tessa et 
al., 2002; Abel et al., 2004; Hedera et al., 2004; D’Amico et al., 2004). In one large 
study looking at the same group of early onset pure HSP families in whom spastin 
mutations had been excluded, Durr and colleagues identified SPG3A mutations in 12 
out of 31 families (39%) from Europe and Africa (Durr et al., 2004). This suggests 
that either the frequency of SPG3 A mutations within this population is significantly
137
higher or that due to the smaller numbers studied in our group SPG3 A mutations were 
underrepresented.
8.8 Mapping of the SPG26 locus
Following the original description of a Kuwaiti family of Bedouin origin with a 
complicated autosomal recessive HSP phenotype (Farag et al., 1994) a follow-up 
clinical study was performed and DNA obtained for linkage analysis. Using a genome 
wide linkage analysis approach a region of homozygosity was identified on 
chromosome 12 flanked by markers D12S345 and D12S326. Marker saturation 
analysis of this region demonstrated a 22.8cM region of homozygosity co-segregating 
with the disease in all affected individuals flanked by markers D12S59 and 
D12S1676. Multipoint LOD scores across the region were significantly positive with 
a maximum score of 5.1 between markers D12S1686 and D12S1702. This region 
included the KIF5A gene, in which a missense mutation (A767G) has previously been 
described in a family with an uncomplicated autosomal dominant form of HSP (Reid 
et al., 2002). Although this was felt unlikely to be responsible for this form of HSP in 
view of the different mode of inheritance and complicated phenotype this had to be 
excluded. Direct sequencing of all 28 exons and splice junctions of the KIF5A gene in 
parents and affected individuals failed to reveal any pathogenic mutations.
The 22.8cM interval at chromosome 12p 11.1-12q 14 was therefore confirmed as a new 
locus for autosomal recessive HSP, designated SPG26. Unfortunately the interval is 
large, containing over 400 known or predicted genes, and the identification of further 
SPG26 linked cases to refine the locus further is likely to be necessary to identify the 
gene responsible for this form of HSP. A further consanguineous Spanish family with 
a complicated HSP phenotype including ataxia, congenital cataracts has been 
putatively linked to the SPG26 locus (Ribai et al., 2005) although maximal multipoint 
LOD scores only reached 2.53 and cannot therefore confidently reduce the critical 
interval. A number of interesting candidate genes are however located within this 
region, including DCTN2 (DCTN1 mutations have previously been identified in a 
hereditary form of motor neurone disease) and if the locus size cannot be reduced a 
candidate gene screening approach may be applied.
138
8.9 Recently identified HSP loci and genes
At the time of examination (October 2007) 38 loci have now been registered at the 
HUGO database (http://www.genenames.org/) and mutations in 15 causative genes 
have so far been identified (table 8.1).
Table 8.1 Current genetic classification of HSP
SPG locus Chromosomal
location
Inheritance Gene
product
Phenotype
SPG1 Xq28 X-linked LI CAM Complicated
SPG2 Xq22 X-linked PLP/DM20 Pure and complicated
SPG3 14q 1 l-q21 AD Atlastin Pure
SPG4 2p22-p21 AD Spastin Pure and complicated
SPG5 8qll.l-q21.2 AR - Pure
SPG6 15qll.l AD NIPA1 Pure
SPG7 16q24.3 AR Paraplegin Pure and complicated
SPG8 8q24 AD Strumpellin Pure
SPG9 10q23.3-q24.2 AD - Complicated
SPG 10 12q 13 AD KIF5A Pure
SPG11 15ql3-ql5 AR - Pure and complicated
SPG 12 19q 13 AD - Pure
SPG 13 2q24-q34 AD HSP60 Pure
SPG 14 3q27-q28 AR - Complicated
SPG 15 14q22-q24 AR - Complicated
SPG 16 Xqll.2 X-linked - Pure and complicated
SPG 17 Ilq l2-q l4 AD BSCL2 Complicated
SPG18 Reserved - - -
SPG 19 9q33-q34 AD - Pure
SPG20 13ql2.3 AR Spartin Complicated
SPG21 15q22.3 AR Maspardin Complicated
SPG22 Reserved - - -
SPG23 Iq24-q32 AR - Complicated
SPG24 13q 14 AR - Pure
SPG25 6q23-q24.1 AR - Complicated
SPG26 12pll.4-ql4 1 AR - Complicated
SPG27 10q22.1-q24.1 AR - Pure
SPG28 14q21.3-q22.3 1 AR - Pure
SPG29 Ip31.1-p21.1 AD - Complicated
SPG30 2q37.3 AR - Complicated
SPG31 2pll.2 AD REEP1 Pure and complicated
SPG32 14ql2-q21 AR - Complicated
SPG33 Reserved - - -
SPG34 Reserved AD - -
SPG35 Reserved AR - -
SPG36 12q23-q24 AD - -
SPG37 8p21.2-ql3.3 AD - Pure
SPG38 Reserved AD - Complicated
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8.9.1 SPG27
In 2004 Meijer and colleagues reported a large French Canadian family in which 7 of 
14 siblings had a pure form of HSP with an age of onset form 25 to 45 years (Meijer 
et al., 2004). All affected individuals had moderate to severe lower limb spastic 
paraparesis with hyperreflexia, extensor plantar responses, and spastic bladders. There 
was also moderate to severe decrease of vibration sense in the feet. Two individuals 
had dysarthria and one was wheelchair-bound. Nerve conduction studies showed 
normal sensory and compound muscle action potentials, but somatosensory-evoked 
potentials were delayed in the two patients studied. Two-point parametric linkage 
analysis identified a putative disease locus (SPG27) on chromosome 10q22.1-q24.1 
(maximum lod score of 4.49 at markers D10S580 and D10S1765). The critical disease 
locus spans approximately 26 Mb between markers D10S606 and D10S1758 and 
partially overlaps with the SPG9 locus. However, the authors noted that SPG9 is 
autosomal dominant and has a complicated phenotype.
8.9.2 SPG28
In 2005 Bouslam and colleagues reported a consanguineous Moroccan family in 
which 3 members had pure spastic paraplegia with distal sensory loss in the lower 
limbs and mild upper limb involvement (Bouslam et al., 2005). Age at onset ranged 
from 6 to 15 years. The patient with earliest onset also had pes cavus and scoliosis. 
Genome wide linkage analysis identified a 6.7cM candidate disease locus between 
markers D14S58 and D14S1064 on chromosome 14q21.3-q22.3 (SPG28). No 
mutations were identified in the SPG3A or the GCH1 gene, both of which map to this 
interval.
8.9.3 SPG29
In the same year Orlacchio and colleagues reported a large Scottish family in which 
19 members were affected with a complicated form of autosomal dominant HSP 
(Orlacchio et al., 2005). The mean age of onset was 15.2 years. Other features 
included sensorineural hearing impairment and neonatal hyperbilirubinemia without 
kemicterus. Six patients had urinary urgency due to detrusor muscle hyperactivity and 
thirteen patients had a hiatus hernia. Genome wide linkage analysis in this family 
identified a 22.3-cM disease locus on chromosome 1 p31.1 -p21.1 (SPG29) flanked by
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markers D1S2889 and D1S248 with a maximum multipoint lod score of 7.80 at 
D1S2865.
8.9.4 SPG30
In 2006 Klebe and colleagues reported a consanguineous family of Algerian origin 
with autosomal recessive HSP complicated by cerebellar ataxia and peripheral 
neuropathy (Klebe et al., 2006). They identified linkage to a 5.1cM interval on 
chromosome 2q37.3 (SPG30) with a maximum multipoint lod score of 3.8 between 
markers D2S2338 and D2S2585. Direct sequencing excluded mutations in the coding 
regions of the STK25 gene.
8.9.5 SPG31 (REEP1)
Later that year Ztichner and colleagues at Duke University Medical Center mapped a 
further HSP locus in two large pure autosomal dominant HSP families to an 8.8Mb 
region between markers D2S139 and D2S2181 at chromosome 2pl2 (SPG31) with a 
combined two point LOD score of 4.7 at marker D2S2951 (Ziichner et al., 2006). 
They then sequenced the entire coding sequence and flanking splice sites of nine 
candidate genes and identified pathogenic mutations in the REEP1 gene in both 
families. Four further REEP1 mutations were identified out of a total of ninety 
additional HSP families screened giving a prevalence of 6.5% in their population 
studied. This would imply that mutations in REEP1 are the third most common cause 
for HSP behind spastin and atlastin.
REEP1 was found to be expressed in a variety of tissues including spinal cord. It 
localises to mitochondria and due to the conserved protein domains it is predicted to 
be a mitochondrial membrane protein with chaperone-like activity similar to the heat- 
shock proteins. Although the precise function of REEP1 has yet to be determined this 
adds further evidence to the role of defective mitochondrial function in the 
pathogenesis of some forms of HSP.
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8.9.6 SPG32 and SPG37
Earlier this year Stevanin and colleagues mapped a further complicated autosomal 
recessive HSP locus to a 30cM region on chromosome 14ql2-q21 (SPG32). The 
phenotype in affected individuals was complicated by mild mental retardation and 
imaging showed cerebellar atrophy and brainstem dysraphia (Stevanin et al., 2007a).
Also this year Hanein and colleagues reported a large French family with pure 
autosomal dominant HSP with an age of onset ranging from 8 to 60 years. Genome 
wide linkage analysis identified a further HSP locus at chromosome 8p21.2-ql3.3 
(SPG37) between markers D8S1839 and D8S1795 with a maximum LOD score of 4.2 
at marker D8S601 (Hanein et al., 2007). Screening of two candidate genes encoding 
kinesin family member 13B and neuregulin failed to identify any pathogenic 
mutations.
8.9.7 Further HSP loci
In the past year a further four HSP loci have been reserved on the Human Gene 
Nomenclature Database (HUGO) confirming the vast genetic heterogeneity of HSP. It 
is hoped that the identification of these and other additional HSP genes will add to the 
understanding of the molecular pathogenesis of this disorder.
8.9.8 KIAA0196 (Strumpellm)
Following the original mapping of the SPG8 locus to chromosome 8q24, Valdmanis 
and colleagues have recently identified three mutations in the KIAA0196 gene from 
within this region in six SPG8 linked HSP families (Valdmanis et al., 2007). Three 
families from North American and one British family all possessed the same V626F 
mutation. The KIAA0196 gene encodes a 1,159 amino acid protein containing a 
spectrin repeat domain (Strumpellin). The spectrin repeat domain is found in the 
spectrin, dystrophin and actin family of proteins where they play a role in binding the 
cell membrane to the cytoskeletal network. The stability of this connection is 
important for intracellular transport processes suggesting that disruption of axonal 
transport may also play a role in this form of HSP although further work is still 
required to further elucidate the function of this novel protein.
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8.9.9 KIAA1840 (Spatacsin)
Also this year Stevanin and colleagues identified ten different mutations in the 
KIAA1840 gene in twelve autosomal recessive HSP families with thin corpus 
callosum linked to SPG11 (Stevanin et al., 2007b). KIAA1840 encodes a novel 
protein (Spatacsin) whose function remains unknown although it has been found to be 
expressed ubiquitously throughout the nervous system.
8.10 Common molecular mechanisms in the pathogenesis of HSP
Advances in the identification of causative genes have increased our understanding of 
a number of overlapping molecular mechanisms underlying the various forms of HSP 
(Crosby and Proukakis, 2002; Reid 2003). Disruption of the corticospinal pathways, 
manifesting in a spastic paraparesis, may result from either abnormal initial 
development or subsequent neurodegeneration.
With mutations in the LI CAM and PLP genes the failure of appropriate neuronal 
migration during development or subsequent myelination results in infantile onset 
disease usually affecting multiple systems. The role of mitochondrial respiratory chain 
dysfunction in neurodegenerative disorders is well established and mutations in 
paraplegin, Hsp60 and REEP1 all provide supportive evidence for this mechanism in 
HSP. Hsp60 and REEP 1 are thought to play a chaperone-like role at the 
mitochondrial membrane. Recent studies have demonstrated that paraplegin is 
involved in ribosome assembly in mitochondria. Paraglegin forms hetero-oligomeric 
complexes with subunits of the homologous Afg312 protein to generate protease 
activity. This then regulates ribosome assembly and translation by controlling 
proteolytic maturation of a ribosomal subunit (Rugarli and Langer, 2006). In yeast 
complementation studies paraplegin deficient cells result in the formation of homo- 
oligomeric Afg312 complexes which are proposed to possess altered substrate 
specificity. This may explain the selective degeneration of certain axons within the 
central nervous system and why in particular paraplegin mutations tend to manifest as 
complicated phenotypes. It is however also likely that the terminal ends of the longest 
axons are particularly vulnerable to defects in energy metabolism.
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Defective cellular trafficking and transport appears to be a major factor underlying 
neurodegeneration in HSP. Spastin, atlastin, NIPA1, KIF5A, spatacsin, spartin and 
maspardin all have proposed functions in various pathways associated with 
intracellular transport processes, particularly those involving microtubule dynamics 
and vesicle transport. Using a yeast two-hybrid approach Reid and colleagues have 
identified that spastin interacts with CHMP1B a protein associated with the 
endosomal sorting complex required for transport-III (Reid et al., 2005). Recent 
studies have also identified that spastin and atlastin are binding partners indicating a 
possible common molecular pathway (Zhu et al., 2006; Evans et al., 2006).
Quite how abnormalities in these processes lead to neurodegeneration in HSP remains 
uncertain. The endocytic pathway plays an important role in the regulation of 
membrane associated receptors, with receptor regulation being dependent on a balance 
between degradation in the lumenal compartment of the multivesicularbody or 
lysosome versus recycling back to the plasma membrane (Katzmann et al., 2002). 
Abnormalities of sorting in the endocytic pathway may therefore result in receptor up 
or down regulation. Defective endocytic transport could therefore cause multiple 
abnormalities in plasma membrane receptor levels and consequent abnormalities in a 
variety of signalling pathways such as apoptosis. The terminal ends of the longest 
axons might be particularly vulnerable to this process, because downstream pathways 
might already be working at near threshold levels in such an extreme environment 
(Reid et al., 2005). It is also possible that abnormalities in endosomal trafficking 
might directly perturb downstream signalling, independent of plasma membrane 
receptor levels. Neuronal maintenance is dependent on neurotrophic survival factors 
released by innervation targets. These survival factors signal by activation of cognate 
receptors on the neuronal presynaptic membrane (Sofroniew et al., 2001). In at least 
some neurones nerve growth factor signalling can be conveyed in specialized early 
endosomes that are transported to the neuronal cell body by retrograde axonal 
transport (Delcroix et al., 2003). Failure of trafficking of the signalling endosome 
could therefore lead to neurodegeneration, again with neurones with very long axons 
could be particularly vulnerable to abnormalities of this type of process (Reid et al., 
2005). The fact that these are highly energy dependent processes may also explain a 
common mechanism associated with mitochondrial respiratory chain dysfunction.
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Similar mechanisms have also been proposed in other motor neurone degenerative 
disorders. For example, Alsin, the protein mutated in a hereditary form of motor 
neurone disease is thought to be involved in membrane-proximity activities of 
GTPases that modulate microtubule assembly and cellular transport in neuronal cells 
(Yang et al., 2001). Another hereditary form of motor neurone disease associated with 
bulbar and spinal muscular atrophy had recently been found to be due to mutation in 
the pl50Glued subunit of dynactin, a microtubule motor protein essential for 
retrograde axonal transport (Puls et al., 2005). Defective intracellular transport 
processes have also been implicated in the pathogenesis of a number of other 
neurodegenerative disorders such as Alzheimer’s disease (Kins et al., 2006) and 
Huntington’s disease (Cowan and Raymond 2006).
8.11 Genetic testing in HSP
To date 11 of the causative genes associated with different forms of HSP have now 
been discovered and this has opened up the possibility of diagnostic testing for 
patients. Spastin mutations account for up to 40% of all cases of autosomal dominant 
HSP and have also been identified in a number of apparently sporadic cases. Spastin 
gene screening is now available in the UK as diagnostic test with the potential for 
screening asymptomatic at risk family members and prenatal diagnosis (Hedera et al., 
2001). These possibilities, however, have to be considered in the context of a 
condition for which there is currently no disease modifying treatment and which may 
vary considerably in disease severity. At the present time genetic testing for other 
forms of HSP is available as a research tool only. In view of the fact that most 
mutations are unique to each individual family sequencing of entire genes is the most 
reliable method of detection and cost is likely to be prohibitive for the less common 
forms of the disease. This method also fails to identify large scale deletions, which in 
the case of spastin may be as common as point mutations (Depienne et al., 2007).
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8.12 Animal models and future treatment possibilities in HSP
The ultimate goal in the advances in molecular genetics and understanding the 
pathological mechanisms underlying neurodegeneration in HSP is the development of 
disease modifying treatments. The development of animal models of 
neurodegenerative diseases is one method of trying to achieve this. In 2003 the 
Drosphila homologue of the human spastin gene (Dspastin) was identified 
(Kammermeier et al., 2003), allowing the development of an insect model of HSP by 
either overexpression or knockout of the gene, producing adult onset locomotor 
impairment and neurodegeneration. Like the human protein, Dspastin regulates 
synaptic microtubule networks (Sherwood et al., 2004). Overexpression leads to 
decreased microtubule stability, whereas loss of Dspastin leads to enhanced 
microtubule stability (Roll-Mecak and Vale, 2005). Recently Orso and colleagues 
have demonstrated that the administration of the microtubule targeting drug 
vinblastine significantly attenuates the phenotype observed in Drosphila models of 
spastin-associated HSP (Orso et al., 2005), giving hope that treatment with Vinca 
alkaloid drugs may modify disease in human patients. However, these drugs are 
extremely toxic which may limit the progress onto human trials. The development of 
safer treatments based on regulating microtubule function therefore represents the 
most likely way forward in terms of drug therapies.
A mouse model for paraplegin-associated HSP has also now been developed. 
Paraplegin deficient mice manifest progressive motor impairment with similar 
pathological evidence of axonal degeneration, morphologically abnormal 
mitochondria and impaired respiratory chain function as seen in human patients 
(Ferreirinha et al., 2004). Recently, using a gene therapy approach, the intamuscular 
delivery of paraplegin through an adenoassociated virus vector has been shown to 
rescue some of the axonal changes seen in paraplegin deficient mice (Pirozzi et al., 
2005). Again, this offers hope that similar techniques may be developed for treatment 
in human patients. However, gene therapy using a variety of vectors remains in the 
early stages for treating human disease and is limited by both safety issues and the 
ability to target delivery of the gene to the appropriate areas, in this case the central 
nervous system. The mouse model does though provide future opportunities for
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testing drug treatments based on neuroprotection or improving mitochondrial 
respiratory chain function.
8.13 Future research directions in HSP
The past few years have seen an exponential rise in our understanding of the genetic 
basis and molecular mechanisms underlying the various forms of HSP. Common 
molecular themes are evolving in the pathogenesis of HSP and other 
neurodegenerative disorders. There are, however, still a large number of HSP loci for 
which the causative gene remains undiscovered and much work remains to be done to 
increase our understanding of precisely how defects in axonal transport and 
mitochondrial respiratory chain dysfunction result in selective neurodegeneration of 
the corticospinal tracts. The search also continues for additional genetic and 
environmental factors accounting for the marked variability in age of onset and 
disease progression so frequently observed among families with HSP. Cellular and 
animal models for some forms of HSP have now been developed and this is likely to 
be the first step towards establishing safe and effective disease modifying treatments, 
although such advances are still likely to be many years away.
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APPENDIX 2
Primers for SPG5A candidate genes
AP3M2 primers
AP3M2 IF gagtcctgaggctttcagac
AP3M2 1R tacacaatggaaacaggactac
AP3M2 2F acagtatctgagtgatcaatg
AP3M2 2R tgtgcgacactcgactaagc
AP3M2 3F ggtgttctgtggtttctagag
AP3M2 3R aagcattatatgaaagaggtc
AP3M2 4F cagagaagtattcagtaatcg
AP3M2 4R tactctgtctttccagcagc
AP3M2 5F tgctttcctgaaagcactgc
AP3M2 5R tcttaatcaccacagatacgg
AP3M2 6F ccagtgcacgaatgaaatgac
AP3M2 6R caaggtctagagtctacacag
AP3M2 7F atgcaggattctgctgtaac
AP3M2 7R tgcgccatatggcagaaagc
AP3M2 8F aacagttaggcgacctgctc
AP3M2 8R tgacctaggagacaggctg
LOC138051 (Paraplegin-like protein gene) primers
PL IF Gcctaaagcagctcttcgtg
PL 1R Ctggaccaccagtgagaatc
PL 2F T caaagccagctgctaccac
PL 2R Ggtgtaaaggtcactcgaac
PL 3F Acttgtcaataactatgtttc
PL 3R T cttctgatggtgcagagc
PL 4F Gtgatgactctttcctgctg
PL 4R T gctcctaggtcttgatactg
PL 5F Ctgtgagaaggccaagctag
PL 5R T aagtctccgactctagctg
PL 6F T caccgttagtggatccgag
PL 6R T atccggttgattggtgctg
PL 7F acactcaaccagctgctggtgg
PL 7R T gtctcgcagcaatctacgc
PL 8F Caggtgctgatgttgctaat
PL 8R Ttgagtgactgcagcgagc
PL 9F T ccacctctgcggcgtcg
PL 9R Cgagctccgtcagaggag
PL 10F Cagcgcgaccagcctgag
PL 10R Ggtgcacttgggcgctgc
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ATP6VH1 primers
ATP6VH1 IF Agtgatcacgatattcataatc
ATP6VH1 1R Atgcaaaagcatatgactgtc
ATP6VH1 2F Aatccaggtctgtctgatgc
ATP6VH1 2R Agcaagaaaactggaagtcac
ATP6VH1 3F Actgaagttccattgaaatgtg
ATP6VH1 3R T gctgctactgtgaggtatg
ATP6 VH1 4F Aggttgagaagtggtgcac
ATP6VH1 4R Agcctggacaacatagtgag
ATP6VH1 5F gagtgttaagaaattgtgtagc
ATP6VH1 5R tagcttaaaagaacacggatg
ATP6VH1 6F gtaagctgatacattaggata
ATP6VH1 6R ctaactggaggtgaccatgg
ATP6VH1 7F attccagtaggtaatctgac
ATP6VH1 7R atgtcaaggagagatgcttg
ATP6VH1 8F tctagctgcttgttattgctg
ATP6VH1 8R atattcaccaagactctatgg
ATP6VH1 9F gtctctgaatccatcacatg
ATP6VH1 9R aacgtattttagtggactctcttg
ATP6VH1 10F ggagtactgtcagattcttata
ATP6VH1 10R tcaaccacattagtcagcaag
ATP6VH1 1 IF caggaagatatcttcattatac
ATP6VH1 11R agttcctttgctaacctactc
ATP6VH1 12F gagctgcctgcttacaaactg
ATP6VH1 12R gcaagtgagagtttgcagac
ATP6VH1 13F atatatgacagtgcataatgtg
ATP6VH1 13R aacagtgttcactcttaact
Syndecan binding protein gene (SBP) primers
SBP IF tcaatttctatgacattagag
SBP1R tataagtagaatgcatgttac
SBP2F gtaagtatagcatattgttag
SBP 2R tcttggattccttatatgagc
SBP 3F aatacgcagaagcccataatg
SBP 3R tgtgagttagccacaaagag
SBP 4F actgagtaagttccagttat
SBP 4R taatcacttattatgtaagag
SBP 5F cgtatcatagtagtggtaaatg
SBP 5R gactataaggctcatcaataac
SBP 6F atccaatatggcaacatttatg
SBP 6R ctgcagcagaacatggcac
SBP 7F tctttaccaagactggcatag
SBP 7R ttaagtcacatgaccatatgc
SBP 8F acaggtgctaaattggaattg
SBP 8R tcctcatgcagcatatgctc
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TRAM primers
TRAM IF gtgagcagctgggaagagc
TRAM 1R gcctgcacctcagggactg
TRAM2F gtgcttcgatttagggacag
TRAM2R catggatgagatctctgacg
TRAM 3F tgtttccataactatgttgtac
TRAM3R cagattatggagagctagtac
TRAM4F gtactagctctccataatctg
TRAM 4R tagcagagtttctaatcttag
TRAM5F tgcaacctggtatgggacc
TRAM 5R gattaatagtgacatgaccatg
TRAM6F tattgtatggaatgatgacac
TRAM 6R atggaggaagggcaaacatg
TRAM 7F ctgggcaacatagcaagac
TRAM7R agacaggtcagcatactatc
TRAM 8F gatagtatgctgacctgtct
TRAM 8R tggcaatgttaggcactgac
TRAM9F gattacaggcgtctgccac
TRAM 9R atgattcaatgtagagaaactg
TRAM 10F tgatagaatgtattcagtggc
TRAM 10R tgtggaatgcagtaagattac
TRAM 1 IF ttctgaaggtatctttacatat
TRAM 11R atcaaagagcacagactgtat
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APPENDIX 3
Details of SPG5A candidate genes
Candidate genes from within the SPG5 A locus were selected based on known or 
predicted gene products with pathways involved in intracellular transport processes or 
mitochondrial function which had been previously implicated in genes responsible for 
different types of HSP. Details of each gene are shown below.
AP3M2
This gene encodes a subunit of the heterotetrameric adaptor-related protein comlex 3 
(AP-3), which belongs to the adaptor complexes medium subunits family. The AP-3 
complex plays a role in protein trafficking to lysosomes and specialized organelles.
LOC138051
LOCI38051 was initially thought to code for a paraplegin-like protein with over 80% 
homology to paraplegin. This has since been recognised as a pseudogene.
ATP6VH1
This gene encodes the vacuolar ATpase H+ transporting VI subunit. The vacuolar 
ATPase is a multisubunit enzyme that facilitates the acidification of intracellular 
compartments and plays a role in receptor-mediated endocytosis, intracellular 
trafficking, and protein degradation. ATP6V1H is a subunit of the 570-kD VI 
peripheral complex responsible for hydrolysis of ATP.
SDCPB
Syndecan binding protein (syntenin) is part of the syndecan group of proteins. These 
are transmembrane proteoglycans that place structurally heterogeneous heparan 
sulfate chains at the cell surface and a highly conserved polypeptide in the cytoplasm. 
Versatile heparan sulfate moieties support various processes of molecular recognition, 
signaling, and intracellular trafficking.
TRAM
Translocation associated membrane protein is involved in the recognition and 
translocation of secretory proteins in the endoplasmic reticulum.
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